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ABSTRACT 
Cervical cancer is the third most commonly diagnosed cancer globally and it has also been 
identified as one of three AIDS defining malignancies. Highly active antiretroviral therapy 
(HAART) is a combination of three or more antiretroviral drugs which are classified as 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). HAART has been shown to 
play a significant role in reducing the incidence of some AIDS defining malignancies, 
although its effect on cervical cancer is still unclear. It is hypothesized that HAART might 
reduce cancer risk by interacting with different signalling molecules and pathways that are 
involved in cancer in order to induce cell death and thus inhibit cell proliferation. The broader 
aim of this study was to understand the relationship between cervical cancer and HAART. 
This was achieved by studying the expression of key signalling molecules in cancer; MUC1 
and NFkB (P65) and morphological features using scanning electron microscopy following 
24 hour treatment of a cervical cancer cell line, HCS-2 with drugs which are commonly used 
as part of HAART; Emtricitabine (FTC), Tenofovir disoproxil fumarate (TDF), Efavirenz 
(EFV), Atripla combination (ATP) and Kaletra combination (LPV/r) at their clinical plasma 
concentrations. Quantitative real time polymerase chain reaction (qPCR) was used in order to 
study the gene expression of MUC1 and P65 and the data was analysed using the 2
-∆∆CT
 
method to calculate fold change. The statistical analysis was conducted using JMP 11 
software. MUC1 and P65 gene expression was reduced following drug treatment. Protein 
expression was studied by means of Immunofluorescence and MUC1 and P65 protein 
expression was reduced following drug treatment. Scanning electron microscopy revealed 
characteristic features of apoptotic cell death such as loss of cell contacts, reduced density 
and size of microvilli, increase in surface blebbing and budding and degradation of apoptotic 
bodies following treatment with all the drugs. In conclusion, the drugs used in this study 
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showed some anticancer effects. The drugs facilitated cell death by decreasing the gene and 
protein expression of MUC1 and P65.  In addition, distinct morphological features 
characteristic of apoptosis and/or secondary necrosis were induced following treatment with 
all the drugs used in this study.  
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CHAPTER ONE: INTRODUCTION 
1.1 GENERAL INTRODUCTION  
1.1.1 Cervical cancer; a public health issue 
Cervical cancer is the third most commonly diagnosed cancer globally among women and it 
is second in developing countries following breast cancer (Jemal et al., 2011; Baiocchi et al., 
2012). More than 80% of women globally who are diagnosed with cervical cancer are from 
developing countries (Yang et al., 2004; Uleberg et al., 2011). Cervical cancer is the fourth 
leading cause of cancer death in women globally and over 85% of the deaths occur in 
developing countries (Jemal et al., 2011). 
High risk Human Papilloma Virus (HPV), for example HPV 16 – HPV 18, infection acquired 
by cervical epithelial cells is the most important risk factor for cervical cancer development 
(Uleberg et al., 2011). Once infected with HPV, the cervical epithelium undergoes 
transformation and develops a non-invasive neoplastic lesion called cervical intraepithelial 
neoplasia (CIN) (Uleberg et al., 2011). Three CIN grades have been identified by the World 
Health Organisation (WHO) namely CIN 1- 3, and they are distinguished by the degree of 
epithelial transformation caused (Uleberg et al., 2011).  
Diagnoses with CIN 2-3 following a histological punch biopsy is usually treated by cone 
excision therapy because often when patients are diagnosed with CIN 2-3, 5-30%  of them 
eventually develop invasive cervical cancer when they are left untreated, so this aggressive 
invasive therapy employed is often mandatory (Uleberg et al., 2011). This does not apply for 
all cases as CIN 2-3 regression occurs in 10-40% of the cases (Uleberg et al., 2011).  The 
tumour itself takes ~10-25 years to develop (Uleberg et al., 2011). 
Women diagnosed with cervical cancer often die at a younger age than those diagnosed with 
any other cancer (Goldie, 2006). It is noteworthy that despite its high mortality rate amongst 
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women globally, cervical cancer can be prevented by vaccination and screening (Xu et al., 
2009; Uleberg et al., 2011). Moreover it is treated effectively by various interventions such as 
cone excision therapy, radiotherapy, chemotherapy and hormone therapy, when identified at a 
sufficiently early stage (Xu et al., 2009; Uleberg et al., 2011).  
In developed countries, higher levels of screening for the early detection of cervical cancer 
has kept its mortality rate low (Anorlu, 2008; Sibiya, 2012). Unfortunately, the opposite is 
true in many developing countries because a majority of them have resource poor settings so 
cytologic screening and vaccination are challenging to implement and sustain; consequently 
mortality from cervical cancer continues to increase (Goldie, 2006; Anorlu, 2008; Sibiya, 
2012).  
Africa has the highest prevalence of and mortality from cervical cancer in the world (Anorlu, 
2008). In South Africa, cervical cancer accounted for 18.10% of new cancer cases in women 
of all races by 2007, making it the second most commonly diagnosed cancer in women 
following breast cancer which accounted for 21.02% of new cases (South African National 
Cancer Registry Report, 2007).  
The high prevalence of cervical cancer in these regions can be attributed to factors including 
lack of vaccination, poor access to medical facilities, poor nutrition and co-morbid 
conditions, for example malaria and human immunodeficiency virus (HIV) infection, 
diagnoses at a later stage of disease, insufficient quality care provided by many health 
services, loss of follow-up and women unable to finish treatment for other sexually 
transmitted infections (STIs) namely Herpes simplex 2, Chlamydia trachomatis and Neisseria 
gonorrhoea which have been linked to increased risk for CIN and invasive cervical cancer 
(Anorlu, 2008). After infecting the cells, these STIs induce a chronic inflammatory response 
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which results in the generation of free radicals which are suggested to play a vital role in 
carcinogenesis (Anorlu, 2008).  
1.1.2 The progression from HPV infection to cervical cancer 
Papillomaviruses are small viruses with a double-stranded deoxyribonucleic acid (DNA); 
they commonly infect and undergo a full infectious cycle exclusively in fully differentiated 
squamous epithelium and its precursors (Villa, 2006; Gomez and Santos, 2007; Stanley, 
2010).  
Papillomaviruses are specific to species like Human Papillomavirus (HPV) and they are 
classified according to genotype (Villa, 2006). Approximately 200 HPV types have been 
identified; a common feature among them is a circular double-stranded DNA genome of 
~8000 base pairs; however, of the 30-40 HPV types that are commonly found in the genital 
tract, only 12 are considered to be carcinogens (Villa, 2006; Gomez and Santos, 2007;  
Stanley, 2010; Baiocchi et al., 2012).  
The small HPV genomes are arranged into an early, late and a long control region (Villa, 
2006). The early control region produces two genes that are essential to the cellular 
transformation and cell immortalization induced by HPV genes E6 and E7 (Villa, 2006). In 
contrast the late control region produces two genes that are critical for encoding the viral 
capsid proteins, genes L1 and L2 (Villa, 2009; Ferenczi et al., 2013). The late control region 
governs the transcription of viral oncogenes of Papillomaviruses (Ferenczi et al., 2013).   
There are various clinical conditions that result from HPV infection, including innocuous 
lesions to cancer; however, the majority of the HPV infections lead to benign tumours 
(Gomez and Santos, 2007). Certain types of HPV are more recurrent in malignant than in 
benign lesions (Villa, 2006). Infection with high-risk HPV types has been identified as the 
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main risk factor for the development of uterine and/or cervix cancer because they promote 
malignant transformation (Villa, 2006; Baiocchi et al., 2012). 
 All high-risk HPV types encode two oncoproteins, E6 and E7, which are responsible for the 
transformation and immortalisation of human epithelial cells (Baiocchi et al., 2012). E6 and 
E7 genes produce oncoproteins E6 and E7 respectively which bind to and inactivate tumor 
suppressor proteins P53 and retinoblastoma (pRb) within the cell (Villa, 2006). The 
prolonged expression of the early proteins, E6 and E7, results in the gradual accumulation of 
defects in the cellular DNA, which promotes malignant transformation (Villa, 2006). Both E6 
and E7 contribute equally to activate epithelial cell transformation (Villa, 2006). 
The alpha genus of HPV has a subset of mucosotrophic HPV types that infect mucosal 
surfaces, for example, high-risk HPV16 and 18 (Villa, 2006). It is these types that account for 
over 99% of cervical carcinomas (Villa, 2006). The viral genome of HPV integrates with the 
host cells chromosomes (Villa, 2006). The expression of viral genes E6 and E7 is higher in 
cells when HPV16 is integrated into the genome; and so they multiply faster in vitro than 
cervical epithelial cells with extra chromosomal HPV16 (Villa, 2006). In invasive cervical 
cancer, HPV16 is detected in 55% of the cases and HPV 18 is detected in 12.8%, making 
these two types the most common HPV types found in invasive cervical cancer (Stanley, 
2010). 
HPV oncoproteins have been shown to activate the nuclear factor kappa beta (NFkβ) pathway 
(Baiocchi et al., 2012). HPV16 E5 facilitates cervical cancer in part by increasing COX-2 
expression through NFkβ and AP-1, whereas HPV16 E6 and E7 increase the expression of 
genes controlled by NFkβ and AP-1 and induces the secretion of precise pro-inflammatory 
and immuno regulatory cytokines (Baiocchi et al., 2012). In addition, HPV16 E6 activates 
NFkβ DNA binding sites (Baiocchi et al., 2012). The significance of NFkβ as a prognostic 
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biomarker has only been identified recently; however, NFkβ expression has long been 
correlated with poor clinical outcomes in many cancers (Baiocchi et al., 2012). 
 
Figure 1.1: An illustration of the progression of HPV infection to cancer. The route of HPV 
infection (yellow dots) on the epithelial mucosa basal cell layer through micro traumas is 
shown in the left-hand panel. Different viral gene products are expressed and E6/E7 proteins 
increase s-phase competent cells thus promoting the amplification of viral genome which will 
result in the synthesis and shedding of new viral particles within 2-3 weeks. In cases where 
persistent infections occur, pre-cancerous lesions are not treated and high levels of viral DNA 
are detected gradually. Finally the host is pre-disposed to the development of cancer. This 
stage is characterised by loss of differentiation, inhibition of viral replication and increased 
levels of E6 and E7 oncoproteins as shown in the right-hand panel (Thomas et al., 2008). 
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1.1.3 The risk and prevalence of cervical cancer in South Africa 
In South Africa (SA), there are approximately 6800 new HPV infections per annum and 
approximately 3700 deaths resulting from cervical cancer annually (Bomela and Stevens, 
2009). This means that cervical cancer is the leading cause of cancer death among women in 
SA (Bomela and Stevens, 2009). The national cervical cancer screening policy in SA is 
aimed at screening a minimum of 70% of women who use public sector services during a 10 
year period by means of the Papanicolaou cytology technique  (Pap smear) (Bomela and 
Stevens, 2009).  
Despite its existence, implementing effective screening programmes has proven to be a 
difficult task, although women are encouraged to undergo Pap smears (Bomela and Stevens, 
2009). The development of the HPV vaccine has provided hope in fighting cervical cancer; 
however, due to its high cost it is not currently available to women who rely on public sector 
services, which is the majority of affected women (Bomela and Stevens, 2009). Therefore 
preventative measures and early detection are often relied upon as strategies to manage this 
disease and prevent its high prevalence (Sibiya, 2012). 
The severity of cervical cancer in South Africa is heightened by the HIV epidemic (Batra et 
al., 2010). HIV positive women have a five times greater chance of developing CIN than HIV 
negative women (Batra et al., 2010). The progression of CIN to cancer occurs rapidly in the 
presence of HIV (Batra et al., 2010). 
1.1.4 Cervical cancer is an AIDS defining malignancy 
Acquired immunodeficiency syndrome (AIDS) has been previously associated with the 
development of certain cancers (Rabkin, 2001; Mbulaiteye et al., 2003). Kaposi’s sarcoma, 
Non-Hodgkin’s lymphoma and cervical cancer are known to be AIDS defining malignancies 
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because they have been observed to occur more frequently in HIV infected people (Rabkin, 
2001; Mbulaiteye et al., 2003). The development of AIDS defining malignancies is mainly 
due to immuno-suppression; however, the risk for cervical cancer is further increased because 
both HIV and HPV are sexually transmitted viruses, therefore they have common sexual 
behavioural risk factors (Rabkin, 2001; Mbulaiteye et al., 2003).  
 A study conducted in Sub-Saharan Africa revealed that cervical squamous intra-epithelial 
lesions and invasive cervical cancer are highly prevalent in HIV-positive women (Firnhaber 
et al., 2012). High-risk HPV infection was found to be dominant among women in Sub-
Saharan Africa and it persisted for a longer duration in HIV positive women (Firnhaber et al., 
2012). In another study it was observed that ~20% to 35% of HIV positive women without a 
history of cervical disease were likely to develop squamous intraepithelial lesions within 3 
years (Sirera et al., 2008). 
HIV positive women in developing countries have had increasing access to highly active 
antiretroviral therapy (HAART) since 1995 and this has substantially improved life 
expectancy and reduced the risk and prevalence of opportunistic malignancies (Julg and 
Bogner, 2008; Sirera et al., 2008; Firnhaber et al., 2012). Studies have shown that HAART 
has significantly decreased morbidity and mortality in HIV patients; however, there is no 
consensus regarding the use of HAART and the development of cervical lesions, because 
some studies have observed no significant increase in cervical pre-cancerous lesions with the 
use of HAART whereas others have observed a significant increase (Sirera et al., 2008; 
Firnhaber et al., 2012). 
1.1.5 The role of apoptosis in cancer and involvement of MUC1 and NFkβ 
Cancer involves the disturbance of tissue growth (Bafna et al., 2010). Normal tissue growth 
is regulated by the balance between cell proliferation and cell death (Bafna et al., 2010). 
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Alteration of the genes that control cell growth and cell death is required for the 
transformation from normal to cancer cells (Bafna et al., 2010).  
Apoptosis is a tightly programmed cell suicide which occurs in multiple physiologic and 
pathological conditions where it plays an important role in tissue development and 
homeostasis by eliminating unwanted and damaged cells (Debatin, 2004; Plati et al., 2008). 
During apoptosis harmful cells, especially those that have been genetically altered, are 
removed, therefore this process maintains the integrity of the organism (Plati et al., 2008).  
The underlying mechanism for the activation of apoptosis is not well understood; however, 
there are common features that have been observed to occur following apoptosis induction, 
such as damage to DNA and/or sub cellular structures (Debatin, 2004). This damage is spread 
by cellular stress which acts upon various molecules such as INK, MAPK/ERK, NFkβ, or 
ceramide and can have a significant impact on apoptosis pathways (Debatin, 2004; 
Mojakgomo, 2012). 
Evasion of apoptosis is the most important hallmark of cancer because appropriate apoptosis 
signalling is crucial in maintaining the fine balance between cell death and cell survival (Plati 
et al., 2008). Tumour development requires defects in the cell cycle which will promote 
uncontrolled proliferation (Plati et al., 2008). On the other hand, cell proliferation is tightly 
controlled and has mechanisms that serve to detect abnormal proliferation by activating 
signalling pathways that induce senescence or apoptosis (Plati et al., 2008). 
 In order to overcome the protective apoptotic signalling response, cancer cells have both 
proliferation-stimulating mutations and defects in the apoptotic pathway which work together 
to deregulate apoptosis (Plati et al., 2008). Alternatively cancer cells cause the signalling of 
aberrantly activated survival pathways as a means to evade apoptosis (Plati et al., 2008). 
Overall, the inhibition of apoptotic signalling provides enhanced survival capacity to cancer 
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cells and is responsible for their characteristic uncontrolled proliferation; consequently it has 
resulted in the development of many anti-neoplastic agents which exhibit their cytotoxic 
effects by inducing apoptosis (Plati et al., 2008).  
Apoptosis is controlled at different levels by various signalling pathways which will 
ultimately integrate into a complex network (Plati et al., 2008). The defects occurring along 
the different apoptotic pathways are targets for new therapeutic strategies for cancer 
treatment (Plati et al., 2008). One of the targets for inhibition of apoptosis in cancer is 
through survival factors (Plati et al., 2008). Survival signalling pathways promote cellular 
proliferation; therefore, they are tightly regulated because they maintain homeostasis of 
healthy tissue (Plati et al., 2008).  
Survival pathways are integrated to apoptotic pathways through intricate signalling pathways; 
however, it has been hypothesised that the activation of survival through signalling pathways 
such as; phosphatidylinositol-3-kinase (PI3K)-AKT, NFkβ, and Ras-RaF-MEK-ERK 
pathways can suppress apoptotic signalling (Plati et al., 2008). This linkage between cell 
survival and cell death pathways is manipulated by cancer cells; they activate survival 
signalling in order to evade an apoptotic response that would normally be activated by stimuli 
such as the removal of growth factors and/or genomic defects (Plati et al., 2008). 
Mucins have been shown to harbour complex relationships with many cellular pathways 
associated with cell growth, proliferation and apoptosis (Bafna et al., 2010). It has been 
established that transformation in cancer refers to either initiation events, which are 
responsible for the early stages of neoplastic transition, or progression events, which refer to 
subsequent transformative processes (Bafna et al., 2010). In addition, over expression and 
down regulation of mucins is often used in order to alter the tumorigenicity and metastasis of 
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various cancer cells in vitro, thus demonstrating their function in cancer pathogenesis (Bafna 
et al., 2010).  
In an attempt to understand the role of HAART in cervical cancer, the relationship between 
key proteins that act as important biomarkers for most cancers and are involved in various 
cellular signalling pathways, MUC1 and NFkβ1 (RelA or P65) (Caiscio et al., 2011), was 
investigated under different antiretroviral drug treatments. The drugs belong to various 
classes which together comprise the HAART cocktail. The information gathered will assist in 
predicting the possible role of HAART in cervical cancer; with respect to cancer risk or 
prognosis with the use of HAART. The following paragraphs will further explain the role of 
MUC1 and NFkβ1 in cancer signalling. 
1.2 LITERATURE REVIEW 
1.2.1 Introduction to the mucin family 
Various mucosal epithelium and hematopoietic cells express transmembrane glycoproteins 
known as mucins on their surface (Banerjee et al., 2012). The mucin family is made up of 
proteins containing tandem repeat structures with a content of prolines, threonines and serines 
(Zaretsky et al., 2006; Kufe, 2009). Furthermore, they characteristically have long 
glycosylations of the proline, threonine and serine domain through GalNAc O-linkages at the 
threonine and serine residues (Gendler, 2001; Zaretsky et al., 2006; Kufe, 2009). The Human 
Mucin family (MUC) consists of secreted and transmembrane forms (Zaretsky et al., 2006; 
Kufe, 2009).  
The first line of defence for most epithelial surfaces is secreted mucins, including MUC2, 
MUC5AC, MUC5B, and MUC6 (Gendler, 2001). Mucins form a selective physical barrier 
between the mucosal surface and extracellular milieu, which becomes a mucous gel and is 
11 | P a g e  
 
responsible for protecting epithelial cells lining the respiratory and gastrointestinal tracts 
(Gendler, 2001; Zaretsky et al., 2006; Kufe, 2009). Additionally, it forms part of the ductal 
surfaces of organs such as the liver, breast, pancreas and kidney (Gendler, 2001; Zaretsky et 
al., 2006; Kufe, 2009). Secreted mucins were first identified in metazoans where they formed 
part of the epithelial barrier and regulated inflammatory response at the interface between the 
epithelium and its environment (Kufe, 2009). Mucins have since evolved as more complex 
transmembrane structures that play a role in the protection, repair and survival of epithelia in 
vertebrates (Zaretsky et al., 2006; Kufe, 2009).  
The transmembrane mucins, including MUC1, MUC4, MUC13 and MUC16, play a role in 
the second line of defence by detecting any disturbance to the environment and transmitting 
this information to the cells interior (Gendler, 2001). They are made up of a single membrane 
spanning region and they have ectodomains of o-glycosylated tandem repeats forming rod-
like structures longer than 100nm from the cell surface, where their function is to form a 
protective mucous gel (Zaretsky et al., 2006; Kufe, 2009). Cancer cells of epithelial origin 
often over express transmembrane mucins and this distorts their function of promoting 
growth and survival (Zaretsky et al., 2006; Kufe, 2009; Banerjee et al., 2012).  
Mucins are well located in order to facilitate interactions between epithelial cells and their 
milieu (Dekker et al., 2002). They function like a potent double-edged sword by preventing 
unwanted substances and organisms from entering the epithelium and simultaneously 
facilitate interactions through their highly complex structures (Dekker et al., 2002).  
Due to their position in cells, mucins are prone to be central in many disease processes, where 
interactions between epithelial cells and their surroundings have been disturbed, often 
including inflammatory and infectious diseases, cancer and metastasis, (Dekker et al., 2002). 
Furthermore, mucins have the ability to initiate transformation and carcinogenesis in animal 
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models, making them highly attractive targets for anticancer treatment (Zaretsky et al., 2006; 
Kufe, 2009). 
1.2.2 The structure and function of MUC1 
MUC1 is translated as a single polypeptide; however, during its auto proteolytic cleavage the 
MUC1 single peptide forms a stable non-covalent heterodimer which consists of an  
extracellular domain (MUC1-N) derived from the alpha subunit and a cytoplasmic tail 
(MUC1-C) derived from the beta subunit (Zaretsky et al., 2006; Kufe, 2009; Banerjee et al., 
2012; Kumar et al., 2012).  
The MUC1-N is made up of 1000-2000 amino acids which are ordered as variable number of 
tandem repeats reaching approximately 200-500nm above the plasma membrane (Gendler, 
2001; Banerjee et al., 2012; Kumar et al., 2012). The extracellular alpha subunit is 
glycosylated and it is mainly responsible for lubrication and the anti-adhesive properties of 
MUC1 on the mucosal surfaces (Meseguer et al., 1998; Zaretsky et al., 2006; Kufe, 2009; 
Kumar et al., 2012). It is also known to block cell-cell and cell-extracellular matrix 
interactions (Meseguer et al., 1998; Zaretsky et al., 2006; Kufe, 2009; Kumar et al., 2012). 
Proteolytic cleavage results in the release of MUC1-N from the cell surface; therefore, 
MUC1-C then acts as a receptor that interacts with various signalling pathways associated 
with transformation and tumour progression (Zaretsky et al., 2006; Kufe, 2009; Kumar et al., 
2012). 
The MUC1-C subunit is made up of a short extracellular domain excluding terminal repeats, 
a transmembrane domain and the cytoplasmic domain (Kumar et al., 2012). Its cytoplasmic 
domain is composed  of 72 amino acids including various tyrosine, serine, and threonine 
phosphorylation sites with the ability to bind to several proteins involved in regulating cancer 
by affecting cell proliferation, apoptosis and transcription of various genes (Bafna et al., 
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2010; Kumar et al., 2012). MUC1 cytoplasmic tail (MUC1-C) has been identified as a role 
player in cell signalling and interacts with important signalling molecules that are involved in 
cell cycle regulation and apoptosis including; EGFR, Wnt-β-catenin, P53, and NFkβ, thus 
adding another degree of functional complexity to MUC1 (Gendler, 2001; Hiscott et al., 
2001; Kumar et al., 2012).  
MUC1-C associates with the main effector of the canonical Wnt signalling pathway, β-
catenin, and causes anchorage independent growth and tumorigenicity (Banerjee et al., 2012). 
When MUC1-C interacts with β-catenin it localises to the nucleus where it interacts with 
many transcription factors and initiates various growth and survival pathways and by so 
doing suppresses various cell death pathways (Banerjee et al., 2012). 
MUC1-C also interacts with the IkB kinase complex resulting in the increase of 
phosphorylation and degradation of IkBα, and consequently assists in the activation of NFkβ; 
blocking apoptosis and inducing transformation (Zaretsky et al., 2006; Kufe, 2009; Bafna et 
al., 2010). 
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Figure 1.2: An illustration of the protein structure of the full length MUC1 protein in relation 
to the plasma membrane and normal expression pattern of MUC1 protein. The left-hand 
panel represents the three domains of MUC1; a long N-terminal extracellular (ecto) domain, 
the length of this domain above the plasma membrane represents the approximate distance 
that most cell surface MUC1 proteins extend into the peri-cellular space; a single membrane 
bound domain (TM); and a C-terminal cytoplasmic domain (CT). The right-hand panel shows 
the list of epithelial and non-epithelial human tissues that normally express MUC1 (Brayman 
et al., 2004). 
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1.2.3 The expression of MUC1 
MUC1 is expressed at low levels at the apical membrane of normal secretory epithelial cells; 
however, following transformation and loss of polarity in various cancer cells it becomes 
highly expressed over the entire surface (Gendler, 2001; Zaretsky et al., 2006; Kufe, 2009; 
Kumar et al., 2012). This event is associated with high metastatic potential and poor 
prognosis (Gendler, 2001; Zaretsky et al., 2006; Kufe, 2009; Kumar et al., 2012).  
Statistics show that ~72% of tissue from new breast cancer patients, and ~66% of tissue from 
deceased breast cancer patients showed expression of MUC1 (Gendler, 2001). For a long 
time MUC1 was thought to be exclusive to epithelial tissues; however, it has recently been 
identified in other tissues, for example, haematopoietic cells (Gendler, 2001). Expression of 
MUC1 is controlled at the transcription level and the MUC1 gene promoter has many 
potential binding sites for regulators of transcription, including NFkβ (Gendler, 2001).  
Although MUC1-C is generally found within the cytoplasm, it can translocate to the nucleus 
where it plays a role in regulating transcription (Kumar et al., 2012). MUC1-C has attracted 
much attention in research due to its participation in intracellular signalling and 
transcriptional regulation and also the observation that it can translocate to the nucleus, unlike 
MUC1-N (Kumar et al., 2012). The interaction of MUC1-C with various signalling 
molecules is thought to be responsible for the oncogenic effects of MUC1 (Bafna et al., 
2010). 
1.2.4 Introduction to the nuclear factor kappa beta family 
Nuclear factor kappa Beta (NFkβ) is a family of transcription factors (Hiscott et al., 2001; 
Huxford et al., 2009; Baiocchi et al., 2012). The human genome encodes five polypeptides 
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which belong to the family of NFkβ subunits; NFkβ 1 (P50/P105), NFkβ 2 (P52/P100), RelA 
(P65), RelB and c-Rel (Hiscott et al., 2001; Huxford et al., 2009; Baiocchi et al., 2012).  
The Rel family polypeptides are structurally related; they all have a conserved 300aa region 
within the Rel homology domain and this domain also contains sequences that are essential 
for forming dimers, DNA binding, nuclear translocation and interaction with heterologous 
transcription factors (Hiscott et al., 2001; Bharti and Aggarwal, 2002). P65, c-Rel and Rel B 
are the only members of the Rel family containing a transcription domain, although all 
members bind to DNA (Bharti and Aggarwal, 2002).  
NFkβ subunits are able to form homo- and or heterodimers occurring mostly in vitro where 
the P50/P65 heterodimer predominantly exists (Hertlein et al., 2005). In contrast to many 
transcription factors, NFkβ is primarily found in the cytoplasm where it is bound to IkB 
inhibitory proteins and is rendered inactive in that state (Hertlein et al., 2005). 
Phosphorylation of IkB by the IkB kinase complex activates the common NFkβ pathway and 
by so doing results in its ubiquitination and proteosome mediated degradation (Baiocchi et 
al., 2012).  
After NFkβ is released and translocates to the nucleus it connects to its targeted genes 
(Baiocchi et al., 2012). NFkβ activation has been observed in many human cancers, as shown 
by high nuclear localisation of NFkβ subunits such as P65 and P50 (Baiocchi et al., 2012). 
NFkβ is suggested to promote cancer development and progression (Baiocchi et al., 2012). 
High NFkβ signalling has the potential to inhibit apoptosis, increase proliferation and activate 
epithelial-mesenchymal transition by activating its target genes (Baiocchi et al., 2012). 
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Figure 1.3: An illustration of the structure of NFkB and as complexes with DNA and IkB. 
(a) The upper row shows domain organisation of P65 (green) and IkBα (purple). NTD=N-
terminal domain, CTD=C-terminal domain, TAD=trans-activation domain. (b) The middle 
row shows the structure the P65/P50 heterodimer and DNA complex. The location of the 
nuclear localisation signal (NLS) is also depicted here. (c) The bottom row depicts the 
structure of P65/P50 heterodimer and IkBα complex. Interaction of the P65/P50 heterodimer 
and IkBα complex results in a helical conformation of the NLS of P65. The P50 subunit 
(Cyan) is used to crystallise the complex and only contains CTD. The right-hand panel shows 
the P65/P50 heterodimer superimposed with DNA or IkBα. The P65 and P50 subunits in 
complex with DNA are shown in black and gray, respectively and when they interact with 
IkBα, the NTD of P65 changes conformation and thereby prevents DNA interaction (Zheng 
et al., 2011). 
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1.2.5 The functions of NFkβ 
NFkβ /IKB family includes transcriptional regulators which mediate the expression of more 
than 100 target genes, many of those genes function in the host immune response (Hiscott et 
al., 2001; Shukla et al., 2004). Proteins which are encoded by these genes are cytokines and 
chemokine receptors needed for immune recognition, antigen presenting proteins, and 
adhesion receptors which play a role in transmigration across blood vessel walls (Hiscott et 
al., 2001; Shukla et al., 2004). NFkβ has been named the central mediator of the immune 
response because it has such a broad role in immunity (Hiscott et al., 2001; Shukla et al., 
2004).  
Besides its extensive role in immunity, NFkβ has been shown to play a role in oncogenesis 
and in regulating apoptosis (Hiscott et al., 2001; Bharti and Aggarwal, 2002). Tumour 
promoters activate the NFkβ pathway and therefore enhance cell survival; however, when it 
is down regulated cells are susceptible to apoptosis resulting from cytokines and 
chemotherapeutic agents (Bharti and Aggarwal, 2002). 
NFkβ pathway presents a potential target against viral pathogens for many reasons; following 
exposure to a relevant inducer NFkβ is activated rapidly and thus leads to the quick 
transcription of many early viral, as well as cellular, genes (Hiscott et al., 2001). Viral and 
bacterial pathogens, cytokines, and stress-inducing agents are but a few stimuli that activate 
the NFkβ/IkB complex and result in its phosphorylation (Hiscott et al., 2001). 
In contrast, NFkβ also regulates promoter activation of selected proapoptotic factors such as 
CD95L, CD95, TRAIL-R1, and TRAIL-R2 and it has been observed that under certain 
conditions NFkβ can promote apoptosis (Debatin, 2004). The cytotoxic effect of 
chemotherapy has been greatly improved by some anticancer treatments that induce the 
transcriptional activity of the NFkβ signalling pathway together with chemotherapy (Debatin, 
19 | P a g e  
 
2004). As, NFkβ potentially induces chemo resistance, therefore the inhibition of NFkβ needs 
to be further investigated, as a novel target against cancer (Debatin, 2004).   
Tumour metastasis is usually the endpoint of carcinogenesis and makes cancer fatal (Bharti 
and Aggarwal, 2002). There is evidence to suggest that the activation of NFkβ promotes 
tumour cell proliferation, invasion, angiogenesis and metastasis (Bharti and Aggarwal, 2002). 
Therefore, inhibition of NFkβ in cancer cells may be targeted for cancer prevention (Bharti 
and Aggarwal, 2002). A combination of chemotherapeutic agents or gamma irradiation with 
NFkβ blockers could potentially be effective cancer therapy and should be further 
investigated (Bharti and Aggarwal, 2002).  
1.2.6 The expression of NFkβ 
The inactive form of NFkβ is found in the cytoplasm composed of three subunits; DNA 
binding P50 and P65 subunits and an inhibitory subunit (IkB) which is attached to P65 
(Bharti and Aggarwal, 2002; Shukla et al., 2004). The inhibitory subunit (IkB) is made up of 
IKK-α, IKK-β, IKK-γ and other unidentified proteins and when it is attached to NFkβ, it 
prevents it from entering the nucleus by concealing nuclear localisation sequence of NFkβ 
(Bharti and Aggarwal, 2002; Shukla et al., 2004). When the inhibitory subunit (IkB) is 
released; NFkβ is activated and it translocates to the nucleus where it binds to target genes in 
the DNA (Bharti and Aggarwal, 2002; Shukla et al., 2004).  
1.2.7 The relationship between MUC1 and NFKβ 
MUC1 over expression allows anchorage independent growth for cancer cells partly by 
activating the NFkβ pathways (Shukla et al., 2004). The MUC1-CT is made up of many 
phosphorylation sites, consisting of seven tyrosine residues, and interacts with various 
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kinases such as glycogen synthase kinase 3β, protein kinase Cδ, c-Src and all members of the 
ErbB family (Thompson et al., 2006).  
Tyrosine phosphorylation plays a vital role in regulating the interaction of MUC1 with other 
proteins (Thompson et al., 2006). Interestingly, in certain cancers it was found that MUC1 
was located in the nucleus where it interacted with and regulated transcription factors, a role 
for MUC1 which was previously regarded unlikely (Thompson et al., 2006). 
These studied have highlighted the significance of investigating MUC1 in a new light i.e. 
probing for new signalling pathways that could be affected by MUC1 and trying to clarify the 
function of MUC1 in those pathways (Thompson et al., 2006). One such pathway is the 
NFkβ pathway (Thompson et al., 2006). 
Silencing MUC1 in human cancers has been shown to reduce the activation of NFkβ P65 thus 
suggesting that MUC1-C plays as role in regulating the NFkβ P65 pathway (Shukla et al., 
2004; Cascio et al., 2011). MUC1 also blocks the inhibitory proteins of NFkβ P65 by binding 
to NFkβ P65 and therefore enhancing its function (Shukla et al., 2004; Cascio et al., 2011). 
1.2.8 An Introduction to the components of Highly Active Antiretroviral Therapy 
(HAART) 
Prior to 1996, prophylaxis was the only available drug treatment used against HIV-1 
opportunistic pathogens and AIDS associated illnesses (Arts and Hazuda, 2012). HIV-1 
treatment has since improved with the development of drugs which inhibit reverse 
transcriptase and protease, which are important enzymes in the HIV life cycle (Arts and 
Hazuda, 2012). Although initially the antiretroviral (ARV) drugs were initially administered 
as monotherapy, they are now administered as a drug cocktail because the efficacy and 
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durability of the drugs is enhanced by combining them into one drug regimen (Arts and 
Hazuda, 2012).  
The introduction of combination therapy known as highly active antiretroviral therapy 
(HAART), which consists of  3 or more antiretroviral drugs taken together, has been effective 
in decreasing morbidity and mortality related to HIV infection and AIDS (Arts and Hazuda, 
2012). HAART has improved the prognosis and reduced the incidence of opportunistic 
infections that are associated with HIV/AIDS, in patients who adhere to the treatment plan 
(Bean, 2005). HAART significantly reduces viral replication and viral load of HIV-1 in the 
plasma to an extent that it becomes undetected; this results in clinically significant restoration 
of the immune system (Arts and Hazuda, 2012). 
The compounds that are used as part of HAART belong exclusively to the class of 
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI), Non-Nucleoside Reverse 
Transcriptase Inhibitors (NNRTI) and Protease Inhibitors (PI) (Bean, 2005). These specific 
drug classes are used in combination because they all target different intracellular steps in the 
life cycle of HIV which are facilitated by two viral enzymes, Reverse Transcriptase (RT) and 
HIV protease (Bean, 2005). 
Reverse transcription occurs 10 hours after HIV infection and the reverse transcriptase 
enzyme was the first to be identified and targeted for novel antiretroviral drug development 
(Arts and Hazuda, 2012). Reverse transcriptase enzyme performs various functions with 
RNA-dependant DNA polymerase, RNase-H, and DNA-dependant DNA polymerase 
activities (Arts and Hazuda, 2012). All these enzymes are integral to the conversion of single-
stranded HIV-1 viral RNA into double-stranded DNA (Arts and Hazuda, 2012). 
The mechanism of action of two classes of ARV agents; NRTIs and NNRTIs is targeted 
against reverse transcriptase (Arts and Hazuda, 2012). Overall there are twelve agents that 
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have been approved which belong to both the classes and they make-up for approximately 
half of all approved antiretroviral drugs (Arts and Hazuda, 2012). NRTIs and NNRTIs 
interact with the enzyme reverse transcriptase at different sites; however, they both target its 
ability to facilitate DNA polymerisation and therefore prevent the production of full-length 
viral DNA (Arts and Hazuda, 2012). 
1.2.8.1 The mechanism of action of Nucleoside/Nucleotide Reverse Transcriptase 
Inhibitors (NRTIs)  
The first class of drugs to be approved by the US food and drug administration (FDA) were 
NRTIs (Arts and Hazuda, 2012). NRTIs are administered as prodrugs, because prior to 
exhibiting their antiviral effect they have to enter the host cell and undergo phosphorylation 
by cellular kinases (Arts and Hazuda, 2012). The sugar (2’-deoxyribosyl) moiety of the 
NRTIs lacks a 3’-hydroxyl group, therefore inhibiting the formation of a 3’-5’-
phosphodiester bond between the NRTIs and arriving 5’-nucleoside triphosphate, as a result 
the newly formed viral DNA-chain is terminated (Arts and Hazuda, 2012). The eight FDA 
approved NRTIs which are currently in use are; Abacavir (ABC, Ziagen), Didanosine (ddI, 
Videx), Emtricitabine (FTC, Emtriva), Lamivudine (3TC, Epivir), Stavudine (d4T, Zerit), 
Zalcitabine (ddC, Hivid), Zidovudine (AZT, Retrovir), and a nucleotide RT inhibitor 
Tenofovir Disoproxil Fumarate (TDF, Viread) (Arts and Hazuda, 2012). 
The structure of NRTIs resembles that of natural nucleosides (Bean, 2005). Therefore 
following its phosphorylation by intracellular enzymes, it competes with natural nucleosides 
for incorporation into the new viral DNA by RT (Bean, 2005). When incorporated, NRTI 
hinders the elongation of the new DNA chain and stops the viral DNA replication process 
(Bean, 2005). 
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Nucleotide reverse transcriptase inhibitors involve two separate chemical steps prior to their 
cellular activation unlike nucleoside reverse transcriptase inhibitors which require three steps, 
in addition Tenofovir is negatively charged therefore it lingers in the cells and is activated for 
a prolonged period (Bean, 2005). 
1.2.8.2 The mechanism of action of Non Nucleoside Reverse Transcriptase Inhibitors 
(NNRTIs)  
The inhibition of HIV-1 reverse transcriptase by NNRTIs is facilitated by binding of the 
drugs close to the active site of reverse transcriptase, therefore causing the formation of a 
hydrophobic pocket (Arts and Hazuda, 2012). When NNRTIs are bound to reverse 
transcriptase, they alter the spatial conformation of the enzymes binding sites and decrease its 
activity (Arts and Hazuda, 2012). The newly formed hydrophobic pocket consists of 
hydrophobic and hydrophilic residues and only binds NNRTIs therefore it is only present 
when there are NNRTIs (Arts and Hazuda, 2012). There are four drugs belonging to this class 
that are currently used for therapy; Etravirine, Delavirdine, Efavirenz (EFV) and Nevirapine 
(Arts and Hazuda, 2012). Other drugs are currently in developmental stages (Arts and 
Hazuda, 2012). 
NNRTIs bind to the reverse transcriptase enzyme downstream from its active catalytic site 
(Bean, 2005). HIV replication is thus inhibited by disturbing the transcriptional activity of the 
reverse transcriptase enzyme (Bean, 2005). The ARVs belonging to this class are more potent 
when co-administered with other ARV drugs (Bean, 2005). 
1.2.8.3 The mechanism of action of Protease Inhibitors (PIs)  
Protease inhibitors (PIs) were the final class of ARVs to be approved for HIV therapy (Arts 
and Hazuda, 2012) and they are active at an advanced stage in the life cycle of HIV, during 
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virus maturation whereby HIV-1 protease plays an important role by cleaving the precursors 
for the polyproteins which will produce the core protein and enzymes of mature viruses, a 
crucial step for the production of infectious viral particles (Bean, 2005; Arts and Hazuda, 
2012). By inhibiting HIV protease activity the infected cell is rendered unable to produce 
infectious viruses (Bean, 2005). 
PIs have been identified as the most effective agents developed thus far; however, they are 
large, peptide like compounds and need to be co-administered with an agent for example 
ritonavir (RTV), that does not significantly contribute to anti-viral activity but will prevent 
the metabolism and therefore enhance the concentration of other PIs in the cells (Arts and 
Hazuda, 2012).  
There are currently ten approved PIs; Amprenavir (APV, Agenerase), Atazanavir (ATZ, 
Reyataz), Darunavir (TMC114, prezista), Fosamprenavir (Lexiva), Indinavir (IDV, crixivan), 
Lopinavir (LPV), Nelfinavir (NFV, Viracept), Ritonavir (RTV, Norvir), Saquinavir (SQV, 
Fortovase/Invirase) and Tipranavir (TPV, Aptivus) (Arts and Hazuda, 2012). Ritonavir 
(RTV) is the only available pharmacokinetic enhancer used currently with PIs however there 
are other drug agents that are being developed for clinical use (Arts and Hazuda, 2012). 
The effects of PIs are enhanced when used alongside reverse transcriptase inhibitors (Bean, 
2005; Israr et al., 2011). In addition, two PIs, instead of one, are now being used more 
frequently because the combination has been shown to increase the potency of the PIs and 
enhance adherence to therapy (Bean, 2005; Israr et al., 2011). The enhanced adherence to 
therapy is attributed to reduced pill burden, because the PI drug combination instead of 
individual pills reduces dose frequency and results in lower treatment costs therefore 
promoting adherence (Bean, 2005). A drug combining two PIs was developed, Kaletra 
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(Abbott laboratories), and it is currently the most frequently prescribed PI combination 
(Bean, 2005; Israr et al., 2011).    
LPV is a PI, and it inhibits the protease of human immunodeficiency virus type 1 (HIV-1) 
(Crommentuyn et al., 2004; Israr et al., 2011; Li et al., 2011). Its structure is derived from 
ritonavir, and they both belong to the same class of ARV drugs and therefore they have 
similar mechanism of action (Crommentuyn et al., 2004; Israr et al., 2011). LPV has poor 
oral uptake and it is extensively and rapidly metabolised by the cytochrome P450 (CYP) 34A 
isoenzyme found in the liver, therefore its bioavailability is very low (Crommentuyn et al., 
2004; Israr et al., 2011; Li et al., 2011). As a result its efficacy is reduced when administered 
alone in ARV regimens (Crommentuyn et al., 2004; Israr et al., 2011).  
Clinically the administration of LPV is coupled with RTV, which potently inhibits the 
activity of hepatic CYP3A4 in order to increase the plasma concentration and efficacy of 
LPV (Crommentuyn et al., 2004; Israr et al., 2011; Li et al., 2011). Currently the RTV-
boosted LPV (LPV/r) regimen is the only PI cocktail that is approved by the FDA to be used 
against HIV infection in adults and children (Crommentuyn et al., 2004; Israr et al., 2011; Li 
et al., 2011). The LPV/r drug cocktail is generally well tolerated and does not result in 
unbearable toxicity (Crommentuyn et al., 2004; Israr et al., 2011; Li et al., 2011). In addition, 
it decreases the total pill burden and therefore promotes adherence and patient acceptance 
(Crommentuyn et al., 2004; Israr et al., 2011; Li et al., 2011).   
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Figure 1.4: An illustration of the important steps in the life cycle of HIV-1 which are potential or current targets for antiretroviral drugs. (a) Schematic 
representation of HIV-1 life cycle in a susceptible CD4+ cell. (b) The time outline for the action of antiretroviral drugs during one cycle of HIV-1 replication.  
(c) A list of pre-clinical (represented by normal text) and FDA-approved inhibitors (represented by bold italic text) relative to specificity of action and drug 
target (Arts and Hazuda, 2012). 
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1.2.9 HIV/AIDS and associated malignancies 
HIV positive women with low CD4+ T-cell counts have been shown to be at higher risk for 
HPV infection, the virus responsible for cervical cancer (Xi and Kiviat, 2004). In addition 
infection with HIV markedly increases the risk of cervical cancer and its precursor lesions, 
high- and low-grade squamous intraepithelial lesions (Xi and Kiviat, 2004). HIV induced 
immunodeficiency leads to the inability to control HPV infection and therefore this partly 
contributes to the development of cervical cancer due to HIV (Xi and Kiviat, 2004). 
Therefore in light of this proposed mechanism, HAART, which restores the immune status of 
HIV positive patients, is suggested to influence the outcome of HPV associated cervical 
lesions in HIV positive women (Xi and Kiviat, 2004). Findings from studies conducted on the 
effect of HAART on cervical lesions are not in agreement (Xi and Kiviat, 2004).   
1.2.10 The effect of HAART on AIDS associated malignancies 
The onset of HAART has led to major improvements in the clinical outcome and life 
expectancy of people infected with HIV/AIDS (Bratcher and Sahasrabuddhe, 2010). It was 
also anticipated that the resultant improved immunological status would lead to enhanced 
clearance of HPV infection in HIV positive women, unfortunately there has been no clear 
reduction in the burden and severity of cervical disease with the use of HAART, unlike other 
AIDS-related malignancies (Bratcher and Sahasrabuddhe, 2010). A better understanding of 
the interactions between HIV, HPV and HAART is becoming even more important because 
HIV positive women who are on HAART therapy are living longer and therefore they are at 
high risk of being infected with invasive cervical cancer (Bratcher and Sahasrabuddhe, 2010). 
Antiretroviral regimens including PIs as part of the drug cocktail have been shown to be 
highly effective in reducing the rate of various opportunistic infections and certain 
carcinomas (Mistro et al., 2004). Despite this invasive cervical cancer has continued to 
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increase in the HAART era, thus suggesting that HAART does not decrease its risk and 
possibly puts women at higher risk due to prolonged life expectancy, where early death 
would have possibly ensued had it not been available (Mistro et al., 2004).  
HIV protease inhibitors have been previously tested against HPV infection and LPV was 
shown to stabilise P53 and induce apoptosis in cervical carcinoma cells infected with HPV 
(Batman et al., 2011). It is noteworthy that the dosages used were higher than those 
accomplished by oral administration however; these results suggest that LPV could act as a 
topical anti-HPV therapeutic (Batman et al., 2011).  
Many viruses including HIV and HPV have been shown to destabilize the function of host 
proteosomes in an effort to remove proteins that would be harmful to viral persistence 
(Batman et al., 2011). E6 and E7 oncoproteins in HPV infected cells are mainly responsible 
for this function (Batman et al., 2011). They assist in destroying certain cellular proteins, e.g. 
P53 and pRb, so as to initiate the viral life cycle (Batman et al., 2011). In general LPV 
changes the level of various proteins which facilitate apoptosis and are regulated by 
proteosomal degradation (Batman et al., 2011). In contrast to these in vitro findings HIV 
patients who are taking oral Lopinavir as part of a drug cocktail, HAART, do not present with 
better clearance of HPV-related lesions (Batman et al., 2011). 
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1.3 RESEARCH OUTLINE 
1.3.1 HYPOTHESIS 
HAART has been shown to play a significant role in reducing the incidence of some AIDS 
defining malignancies, although its effect on cervical cancer is still unclear (Bratcher and 
Sahasrabuddhe, 2010). Immune reconstitution resulting from HAART has been attributed this 
function (Bratcher and Sahasrabuddhe, 2010); however, it is also possible that HAART might 
reduce cancer risk by interacting with different signalling molecules and pathways that are 
involved in cancer in order to induce cell death and thus inhibit cell proliferation. The 
hypothesis states that HAART plays a role in regulating the expression of MUC1 and P65; 
key signalling molecules in cancer (Caiscio et al., 2011), in order to induce cell death.  
1.3.2 RESEARCH QUESTIONS 
 Does HAART increase or decrease the gene expression of MUC1 and P65? 
 Does HAART change the protein expression pattern of MUC1 and P65? 
 Do gene and protein expression of MUC1 and P65 correlate? 
 Does HAART induce morphology characteristic of cell death in HCS-2 cells, and if 
so what type of cell death was induced? 
1.3.3 AIMS AND OBJECTIVES 
The aim of this study was to examine the expression of MUC1 and NFkβ1/ P65 in cervical 
cancer cells (HCS2) following treatment with HAART. MUC1 has been widely studied and 
targeted for therapy in a variety of cancers due to its unique structure which allows it to 
participate in various cell signalling pathways, Its involvement in the NFkβ pathway has not 
been widely studied therefore this study will investigate the relationship between MUC1 and 
a member of NFkβ family, P65 (RelA), when treated with the components of HAART in 
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order to better elucidate the role of HAART in cervical cancer.  The outcome of this study 
will add new knowledge regarding the role of HAART in cervical cancer. In addition it will 
provide novel potential targets against cancer.  
The objectives of the study were; 
i) To quantify and compare the gene expression of MUC1 and P65 using 
quantitative real time Polymerase Chain Reaction (qPCR) following combination 
treatment with drugs classified as NRTIs, NNRTI and PIs 
ii) To study and compare the protein expression of  MUC1 and P65  following 
treatment with the various drugs using Laser Scanning Confocal Microscopy 
iii) To study and compare the changes in the cell surface morphology of HCS-2 cells 
following drug treatment using the Scanning Electron Microscope. 
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CHAPTER TWO: METHODS AND MATERIALS 
2.1 Cell culture 
Human Squamous Cell carcinoma from Uterine Cervix, HCS-2 cell line was purchased from 
the Japanese Collection of Research Bioresources (JCRB) cell bank (National Institute of 
Health Sciences, Tokyo, Japan). The cells were routinely grown as a monolayer in Nunc 
tissue culture grade flasks of 25cm
2
 or 50cm
2
 (Thermo Scientific, Pittsburgh, PA, USA). The 
cells were maintained in a humidified environment of 5% CO2 at a temperature of 37°C in 
Eagle’s Minimal Essential Medium (EMEM) (Lonza, Basel, Switzerland) supplemented with 
15% foetal calf serum (GIBCO, Darmstadt, Germany). The cells were incubated for 
approximately 2 days or until they reached ~ 60-80% confluency and were then harvested 
with 0.1% trypsin and 0.02% EDTA and seeded onto coverslips or they were frozen down in 
the culture medium supplemented with 5% DMSO (SIGMA, St Louis, MO, USA). 
2.2 Cell counting 
The cells were counted using a haemocytometer (Masters and Stacey, 2007). Following 
trypsinisation a cell pellet was collected at the bottom of a 10ml tube by centrifuging at 1250 
rpm for 5mins. The cell pellet was re-suspended in 1ml media and 10µl of the cell suspension 
was diluted with 40µl of Trypan blue in a 1.5ml Eppendorf tube (Greiner Bio-One, 
Frickenhausen, Germany). The solution was vortexed and 20µl of the cell suspension was 
pipetted onto the haemocytometer grid. Viable cells excluded the Trypan blue dye whereas 
dead cells engulfed it, allowing the dead cells to be excluded during counting. An estimate of 
the cell density was calculated (Appendix I). Following cell counting the volume of cells 
needed to attain the desired cell density per coverslip was determined (Appendix I). 
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2.3 Drug preparation 
2.3.1 Rationale for the chosen ARV drugs; The antiretroviral drugs used in the current 
study were chosen because they are widely used clinically (Clay et al., 2008; Horberg and 
Klein, 2010) and administered individually or as a drug cocktail in the form of a single pill 
known as Atripla consisting of Emtricitabine (FTC), Tenofovir disoproxil fumarate (TDF), 
and Efavirenz (EFV) and/or Kaletra which consists of Lopinavir (LPV) and Ritonavir (RTV) 
(Atripla
®
, 2006; Clay et al., 2008; Horberg and Klein, 2010; Kaletra
®
, 2010). Emtricitabine 
(FTC) (Emtriva, 2003), Tenofovir disoproxil fumarate (TDF) (Viread
TM
, 2001), Efavirenz 
(EFV) (Atripla, 2006), Lopinavir (LPV) and Ritonavir (RTV) (Kaletra
®
, 2010) were 
purchased from Toronto Research Chemicals (North York, Canada).  
Drug concentrations; The mean steady-state peak plasma concentration (Cmax) is the most 
physiologically relevant concentration for the ARVs because it represents naturally occurring 
concentrations of the drugs following their intake (Viread
TM
, 2001; Emtriva, 2003; Atripla
®
, 
2006; Kaletra
®
, 2010), hence it was used to treat the cells for 24 hours. Cmax concentrations 
are as follows for the drugs; 
 FTC; Cmax= 1.8 µg/ml (Emtriva, 2003) 
 TDF; Cmax= 0.3µg/ml (VireadTM, 2001) 
 EFV; Cmax= 4.07 µg/ml (Atripla
®
, 2006) 
 RTV; Cmax= 2.45 µg/ml (Kaletra
®
, 2010) 
 LPV; Cmax= 9.8 µg/ml (Kaletra
®
, 2010) 
 Cocktail 1; 1.8 µg/ml FTC + 0.3µg/ml TDF + 4.07 µg/ml EFV  
 Cocktail 2; 2.45 µg/ml RTV + 9.8 µg/ml LPV  
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2.3.2 Drug solutions; The drugs were initially dissolved in 1ml of primary diluent; 
3600µg/ml FTC and 600µg/ml TDF were dissolved in distilled water whereas 6000µg/ml 
RTV, 98000µg/ml LPV and 40700µg/ml EFV were dissolved in methanol (diluents were 
specified in the certificate of analysis obtained from Toronto Research Chemicals Inc. for 
each drug). The drugs were further diluted in EMEM in order to obtain the desired Cmax 
concentrations as indicated above. The final concentration of methanol in working solution 
was 0.02%. 
2.4 MUC1 and P65 gene expression 
2.4.1 RNA extraction; The Gene-JET RNA Purification Kit purchased from Thermo 
Scientific was used to isolate RNA from cells and the manufacturer’s protocol was followed. 
RNA was isolated from a minimum of 1X10
6
cells/ml. Following a 24 hour treatment with 
appropriate drugs (ATP and LPV/r), the growth medium (EMEM) containing the drugs were 
removed from the cells and the cells were rinsed once in PBS (pH 7.4) in order to remove 
residual medium. The cells were then harvested in trypsin EDTA and transferred to an 
RNAse-free microcentrifuge tube (Whitehead Scientific) following which the RNA 
extraction procedure was followed to isolate RNA from the cells (Appendix II). An aliquot of 
5µl was prepared in order to measure the RNA concentration in the samples using a 
Nanodrop spectrophotometer (Appendix II; table 7.1). Genomic DNA was removed from all 
RNA samples isolated prior to complimentary DNA (cDNA) synthesis (Appendix II).  
2.4.2 cDNA synthesis; The high capacity cDNA reverse transcriptase kit purchased from 
Applied Bio-systems was used to synthesize cDNA and the manufacturer’s protocol was 
followed (Appendix II). 
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2.4.3 Primers; Primer sequences for MUC1 and P65 were obtained from Primer Bank and 
those for the reference genes RPLPO and TFRC (Adefolaju et al., 2013) were kindly donated 
by Ms Therese Dix-Peek from the Department of Internal Medicine, University of the 
Witwatersrand.  
Table 2.1: Oligonucleotide sequences used for qPCR. 
Gene Sequences (5’-3’ direction) Gene Bank Accession number 
MUC1 F: TGC CGC CGA AAG TAC G 
R: TGG GGT ACT CGC TCA TAG GAT 
NM_001204294 
P65 F: GTG GGG ACT ACG ACC TGA ATG 
R: GGG GCA CGA TTG TCA AAG ATG  
NM_001145138 
RPLPO F: TGC AGC TGA TCA AGA CTG GAG 
ACA 
R: TCC AGG AAG CGA GAA TGC AGA 
GTT 
NM_053275.3 
TFRC F: GGC ACC ATC AAG CTG CTG AAT 
GAA 
R: GTT GAT CAC GCC AGA CTT TGC 
TGA 
NM_003234.2 
MUC1= Mucin 1, cell surface associated; P65= Transcription factor P65 (RELA); RPLPO= 
Large Ribosomal Protein PO; TRFC= Transferrin receptor. 
2.4.4 Real Time PCR; The Power SYBR
® 
Green PCR Master Mix was purchased from 
Applied Biosystems (Carlsbad, CA, USA) and the RT-PCR master mix was prepared as 
indicated in table 2.2 below. The final reaction volume was 20µl per tube and the tubes were 
centrifuged at 3000rpm for 3 minutes in a U-320 BOECO microcenrifuge before starting the 
PCR reaction.  
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Table 2.2: The composition of the qPCR reaction tube. 
 Volume per reaction tube (µl) 
SYBER green master mix 10 
Forward primer 0.4 
Reverse primer 0.4 
cDNA 4 
H2O (nuclease free) 5.2 
Total 20 
 
The PCR reaction was carried out in the Applied Biosystems (AB) 7500 real time PCR 
system thermocycler and 40 amplification cycles were run under the following cycling 
conditions (as indicated in the Power SYBR
® 
Green PCR Master Mix user guide, 2011). 
There were two technical repeats and the experiments were conducted in triplicates per 
sample. 
Table 2.3: The thermal cycler conditions for the qPCR reaction. 
 Hold Denature Anneal/ Extension 
Temp °C 95 95 60 
Time 10 minutes 15 seconds 1 minute 
 
2.4.5 Data analysis; The 2
-∆∆CT
 method was used in order to calculate the fold change in 
gene expression relative to the control following treatment with the ARV drugs (Livak and 
Schmittgen, 2001). The data was first normalised using two reference genes (RPLO and 
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TRF1) and then the fold change was calculated. JMP11 software was used in order to conduct 
the statistical analysis on the data; an F-test (Brown-Forsythe test) was conducted in order to 
check whether the variances were equal. If there was a significant difference observed in the 
variance the data was transformed using log base10 in order to normalise it (Keen, 1995). A 
one way ANOVA test was conducted and where there was a significant difference observed, 
a Tukey Kramer Post Hoc test was further conducted in order to determine where the 
differences occurred. 
2.5 Immunocytochemistry for the protein expression of MUC1 and P65  
2.5.1 Cell seeding and drug treatment; Approximately 1X10
5
cells/ml were seeded and left 
overnight in order to attach. They were then supplemented with more EMEM the following 
day and left in the incubator until they reached ~50% confluency (~1 day). The media was 
removed and cells were rinsed 3X in PBS (pH 7.4) and treated for 24 hours with the 
appropriate ARV drugs. Following the drug treatment, the media containing the drugs were 
removed and cells were rinsed in PBS (pH 7.4). The cells were fixed in 4% 
Paraformaldehyde (PFA) for 15 minutes at room temperature (RT). The cells were then 
rinsed 3 times in PBS (pH 7.4) for 5 minutes each (Thabethe et al., 2013). There were three 
technical repeats per run and the experiments were conducted six times. 
2.5.2 Controls; the negative control consisted of untreated cells, whereas a positive control 
was MCF7 breast carcinoma cells because they are known to express MUC1 as it plays an 
integral role in breast cancer (Bitler et al., 2009; Gil et al., 2013). Experimental control 
consisted of samples whereby the primary antibodies were omitted in order to determine the 
amount of unspecific binding of the secondary antibodies.  
2.5.3 Antigen retrieval and permeabilisation; citrate buffer (pH 6), was heated to 95°C and 
coverslips containing cells were placed in the citrate buffer (pH 6) for 10 minutes. Then they 
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were rinsed 3 times in PBS (pH 7.4) and permeabilised in 0.25% Triton-X100 in PBS (pH 
7.4) at RT for 20 minutes.  
2.5.4 Immunostaining; The cells were then rinsed 3 times in PBS (pH 7.4) and blocked in 
10% goat serum in PBS (pH 7.4) for 1 hour at RT. Primary antibodies were prepared during 
the blocking period according to the optimised dilutions (Appendix III) and following which 
the cells were incubated with the primary antibodies; Anti-MUC1 rabbit monoclonal 
antibody (Abcam, Cambridge, United Kingdom) at a dilution of 1/150 and Anti-NFkB p65 
mouse monoclonal antibody (Abcam, Cambridge, United Kingdom) at a dilution of 1/250 
overnight at 4°C. Following the overnight incubation, the primary antibodies were removed 
and cells were rinsed 3 times in PBS (pH 7.4) and incubated with secondary antibodies; goat 
polyclonal to rabbit IgG conjugated with TRITC (Abcam, Cambridge, United Kingdom) and 
goat polyclonal to mouse IgG conjugated with FITC (Abcam, Cambridge, United Kingdom) 
for 2 hours in the dark at RT. Thereafter the secondary antibodies were removed and cells 
were rinsed 3 times in PBS (pH 7.4) and the nuclei were stained with 4’, 6-diamidino-2-
phenylindole, dihydrochloride (Dapi) for 10 minutes at a dilution of 1/10000.  
2.5.5 Specimen mounting; The samples were rinsed in distilled water following the final 
rinse in PBS (pH 7.4), in order to get rid of excess salts. Excess liquid was removed from the 
specimen with filter paper by capillary action, then a small drop of Fluoromount (SIGMA, St 
Louis, MO, USA) was placed on the slide, the coverslip was then carefully lowered onto the 
slide in order to minimise formation of bubbles. Excess mounting media was collected by 
small filter paper pieces which were placed at the edges of the coverslips.  The edges of the 
coverslips were sealed with nail polish and the slides were wrapped in foil in order to prevent 
bleaching of the fluorochromes upon exposure to light and they were stored at -20°C 
(Johnson, 2012).  
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2.5.6 Imaging and analysis; The cells were then viewed under a Zeiss LSM 780 confocal 
microscope and cells were visually analysed for the region of localisation of MUC1 and P65 
proteins. Protein expression was compared between the treated cells and controls based on 
the fluorescence intensity of the protein markers and the location of specific fluorescence 
staining within the cells.  
2.6 Surface morphology 
2.6.1 Seeding and drug treatment; Approximately 1X10
5
cells/ml were seeded onto 
22X22mm glass coverslips (Menzel-Gläser, Braunschweig, Germany) and left overnight in 
order to attach. They were then supplemented with more EMEM the following day and left in 
the incubator until they reached ~50% confluency (~1 day). The media was removed and 
cells were rinsed 3X in PBS (pH 7.4) and treated for 24 hours with the appropriate ARV 
drugs. Following the drug treatment, the media containing the drugs were removed and cells 
were rinsed in phosphate buffer (pH 7.4). There were three replicates per samples and the 
experiment was repeated three times. 
2.6.2 Fixation; the cells were fixed for 30 minutes in 2.5% Glutaraldehyde (Agar Scientific, 
Stansted, United Kingdom), rinsed in phosphate buffer and treated with 1% Osmium 
tetroxide (Agar Scientific, Stansted, United Kingdom) for 10 minutes. The cells were rinsed 
in dH2O and treated for 5 minutes with 1% Thiocarbarhydrizide, acts as a ligand and 
enhances the binding of Osmium and the conductivity of the sample by increasing the 
generation of secondary electrons (Murakami et al., 1987; Jongebloed et al., 1999), rinsed in 
dH2O, then treated with 1% Osmium tetroxide for 5 minutes and then rinsed in phosphate 
buffer (pH 7.4).  
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2.6.3 Dehydration and coating; The cells were then dehydrated through a graded series of 
alcohols; 50%, 70%, 80%, 95% and 3X 100% for 5 minutes each. Then treated with 
hexamethyldisilazane (HMDS) (SIGMA, St Louis, MO, USA) for 30 seconds and kept in a 
desiccator containing silica gel until the samples were coated. The cells were then coated 
with a double layer of carbon by an EMITECH K950X. 
2.6.4 Imaging and analysis; HCS-2 cells were viewed under a Zeiss Ultra FEG Scanning 
Electron Microscope and descriptive and statistical analysis were conducted on the surface 
morphology of the cells. A scoring system was established and used in order to analyse 
differences in cell contacts, microvilli density and size, blebbing density and size, and 
presence of cell secretions. The JMP11 software was used in order to conducts the statistical 
analysis following the descriptive analysis and a one way ANOVA test and a Tukey Kramer 
Post Hoc test were used.  
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Table 2.4: Scoring system used in order to analyse surface morphology of the cells 
Surface characteristics Scoring system 
Microvilli density Relative distribution of microvilli on the 
cell surface; 1= sparse, 2=medium, 3= dense 
Microvilli size Relative length of microvilli on the cell 
surface; 1= short, 2= mixture of short and 
long microvilli, 3= long and thin microvilli 
Cell contacts Relative percentage of long and thin 
cytoplasmic projections (e.g. Filopodia)per 
cells and connections between adjacent 
cells; 1= ~0-20% of projections from the cell 
surface and there are less connections to 
adjacent cells, 2= ~21-50% of projections 
from the cells surface and many of them are 
disrupted therefore are not a lot of 
connections formed between the cells, 3= 
~51-100% of projections from the cells and 
many cell connections between adjacent cells 
Blebbing density Relative distribution of blebs/surface 
protrusions on the cell surface; 1= none, 2= 
sparse, 3= medium, 4= dense 
Bleb size Relative size of blebs/ surface protrusions 
on the cell surface;1= none, 2=small, 3= 
medium, 4= large 
Cell shape Change in cell shape; 1= round, 2= oval, 3= 
flattened 
Membrane bound secretions Relative amount of secretions on the 
surface of the cell; 1= none, 2= few, 3= 
moderate, 4= abundant 
Extracellular secretions Relative amount of secretions on the 
extracellular space; 1= none, 2= few, 3= 
moderate, 4= abundant  
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CHAPTER THREE: RESULTS 
3.1 MUC1 and P65 gene expression in HCS-2 cells using real-time polymerase chain 
reaction (qPCR) 
The expression of MUC1 and P65 was examined following treatment with the drug 
combinations making up HAART namely; Atripla (which consists of one NNRTI and two 
NRTI’s) and Kaletra (which consists of two PI’s). MUC1 plays an important role in cell 
signalling and promotes cell growth in various cancers (Banerjee, et al., 2012). P65 is a 
transcription factor which is responsible for controlling cell growth and differentiation, when 
its expression is low it promotes apoptosis (Shukla, et al., 2004; Bharti and Aggarwal, 2002).  
Negative controls whereby the template DNA was substituted for water were included in the 
experiments in order to determine whether there was contamination or non-specific 
amplification in the reagents. The results showed that there was no amplification in the wells 
whereby the template DNA was omitted, therefore the reagents were not contaminated with 
foreign DNA.   
An F-test (Brown-Forsythe test) was conducted in order to check whether the variances were 
homogenous. P-values obtained; P= 0.07 for MUC1 and P= 0.02 for P65 rejected the 
assumption of homogeneity of variances. In order to normalise the data, it was transformed 
using log base10 (Keen, 1995). The transformed values were used in order to analyse fold 
difference in MUC1 and P65 expression and a one way ANOVA test was conducted. 
Overall there was a decrease in the expression of MUC1 and P65 following treatment with 
the diluent, and the drug treatments (ATP and LPV/r) as indicated in table 3.1 and 3.2. The 
fold change for MUC1 expression following treatment with the diluent, ATP and LPV/r was 
0.7-fold, 0.8-fold and 0.2-fold respectively. This suggests that there was a 0.3 (30%), 0.2 
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(20%) and 0.8 (80%) down-regulation in MUC1 following treatment with diluent, ATP and 
LPV/r respectively. The fold change for P65 expression following treatment with the diluent, 
ATP and LPV/r was 0.5-fold, 0.6-fold and 0.1-fold respectively. This suggests that there was 
a 0.5 (50%), 0.4 (40%) and 0.9 (90%) down-regulation in P65 following treatment with 
diluent, ATP and LPV/r respectively.  
The statistical data in table 3.3 show that there was a significant difference in the fold change 
for MUC1 expression following drug treatment (P<0.05). Although P65 was down-regulated 
following treatment with diluent, ATP and LPV/r  as shown in table 3.2,  the statistical test 
showed that the fold change for P65 expression was not significantly different between the 
different groups (P>0.05). 
A Tukey-Kramer Post Hoc test was conducted for MUC1 and P65 expression (Appendix II; 
table 7.6 and table 7.7), in order to compare the means and the results showed that there was 
a significant difference observed in fold change between cells treated with the PI combination 
(i.e. LPV/r) and the other groups (i.e. untreated, 0.02% methanol and Atripla) suggesting that 
MUC1 down-regulation was higher in this group (PI) than any other. There was no 
significant difference observed in P65 expression. 
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Table 3.1: The fold change for MUC1 expression following treatment with various antiretroviral drugs. The values were calculated using the 2
-∆∆CT
 method. 
Sample MUC1 Ave Ct HKG Ave Ct 
∆Ct MUC1- 
HKG 
∆∆Ct= ∆Ct (treated) - ∆Ct 
(untreated) 
Fold change (RQ) 
2
-∆∆CT
  
RQ 
min 
RQ 
max 
Negative control  21.27 ± 0.20 18.10 ± 1.67 2.27 ± 0.51 0 ± 0.51 1 0.72 1.46 
Diluent control 22.24 ± 0.16 19.40 ± 0.59 2.84 ± 0.63 0.56 ± 0.63 0.7 0.48 1.06 
ATP 21.35 ± 0.19 18.68 ± 0.69 2.67 ± 0.80 0.40 ± 0.80 0.8 0.45 1.33 
LPV/r 21.00 ± 0.14 16.37 ± 0.84 4.63 ± 0.86 2.36 ± 0.86 0.2 0.11 0.42 
 
 
Table 3.2: The fold change for P65 expression following treatment with various antiretroviral drugs. The values were calculated using the 2
-∆∆CT
 method. 
Sample P65 Ave Ct HKG Ave Ct 
∆Ct P65- 
HKG 
∆∆Ct= ∆Ct (treated) - ∆Ct 
(untreated) 
Fold change (RQ) 
2
-∆∆CT
 RQ min 
RQ 
max 
Negative control  20.67 ± 0.36 19.00 ± 0.56 1.67 ± 0.69 0 ± 0.69 1 0.63 1.62 
Diluent control 21.40 ± 0.23 19.40 ± 0.59 2.00 ± 0.65 0.33 ± 0.65 0.5 0.52 1.27 
ATP 24.89 ± 1.36 18.68 ± 0.69 6.21 ± 1.71 4.54 ± 1.71 0.6 0.38 1.05 
LPV/r 21.10 ± 0.11 16.37 ± 0.84 4.61 ± 0.85 2.94 ± 0.85 0.1 0.07 0.32 
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Table 3.3: Analysis of variance on the transformed data, using a one way ANOVA test for 
MUC1 and P65 expression 
Source DF Sum of Squares Mean Square F Ratio Prob> F 
  
MUC1 
& 
P65  MUC1  P65  MUC1  P65  MUC1  P65  MUC1  P65  
Group  3  0.73222500  4.571100  0.244075  1.52370  23.9289  0.5149 
0.0002* 
 0.6834 
Error  8  0.08160000  23.672267  0.010200  2.95903         
C 
Total  11  0.81382500  28.243367             
*= p value is significantly different 
 
Figure 3.1: The effects of antiretroviral drugs (Atripla and Kaletra combinations) on MUC1 
and P65 expression following 24 hours treatment. The fold change for MUC1 expression 
between the groups show that there was a significant difference observed (P<0.05); the 
protease inhibitor combination, LPV/r, significantly reduced MUC1 expression in 
comparison to the controls and ATP treatment. In contrast there was no significant difference 
observed (P>0.05) in fold change for P65 between the different groups, however; treatment 
with the diluent control and the drugs reduced P65 expression. Bar graphs not connected by 
the same letter (per characteristic) are significantly different, Tukey Kramer Post Hoc 
analysis. 
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3.2 Immunofluorescence for MUC1 and P65 proteins in HCS-2 cells following treatment 
with antiretroviral drugs 
The cytoplasmic tail of MUC1 plays an important role in cell signalling and has been shown 
to interact with many transcription factors where it initiates various growth and survival 
pathways and by so doing suppresses various cell death pathways (Banerjee et al., 2012). It 
has also been linked to metastasis (Banerjee et al., 2012). NFkβ1 (P65) is a transcription 
factor that is responsible for growth control, differentiation and apoptosis; however, when it 
is down regulated cells are susceptible to apoptosis resulting from cytokines and 
chemotherapeutic agents (Shukla et al., 2004; Bharti and Aggarwal, 2002). 
MUC1 and P65 were co-localised in the HCS2 cell line following drug treatment with FTC, 
TDF, EFV, and drug combinations; ATP and LPV/r. The antibody used for MUC1 was 
specific to the cytoplasmic domain of MUC1 whereas in its inactive form P65 is highly 
expressed in the cytoplasm and relocates to the nucleus when activated (Banerjee et al., 
2012). Therefore MUC1 staining was expected to be detected in the cytoplasm and if P65 
was activated then it’s staining was expected to be found in the nucleus as well.  
Negative controls (untreated cells) showed a positive expression of MUC1 throughout the 
cytoplasm; it was highly expressed towards the periphery of the cell and expression was seen 
also along the cell extensions forming contacts with adjacent cells. P65 was highly expressed 
in the perinuclear region, since it is mainly active in the nucleus. This location is fundamental 
to its role because its close proximity to the nucleus ensures that it relocates to the nucleus 
promptly and with ease when activated (Fig3.2).  
The diluent control (0.02% Methanol) reduced the expression of MUC1 and P65 (Fig3.3). 
MCF7 cell line was used as a positive control in order to validate protein expression because 
the proteins of interest, MUC1 and P65 are known to be expressed in breast cancer (Cascio et 
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al., 2011). Quality control of the secondary antibody was also included by omitting the 
primary antibodies in order to determine whether the secondary antibodies bind non-
specifically to other targets within the cell and as observed in the photomicrograph, Fig3.4-
3.5, there was no non-specific binding.  
In drug treated cells, (FTC, TDF, EFV, ATP and LPV/r) there was a relatively decreased 
expression of MUC1 and P65 in comparison to the controls. MUC1 expression was not vastly 
distributed within the cytoplasm in treated cells, but mainly localised at the perinuclear region 
and p65 expression was reduced in the cytoplasm and not observed in the nucleus, the 
expression of both proteins appeared relatively down regulated with drug treatment in 
comparison to the controls. Although the degree of reduction appeared to be more variable 
for MUC1 expression because the drugs did not all have a similar effect on its expression. 
FTC, EFV and LPV/r treatments reduced MUC1 expression more than TDF and ATP (Fig 
3.7-3.11). In contrast the degree of reduction for P65 appeared to be similar for most drug 
treatments, with exception for ATP treatment because it reduced it more than the other drugs 
(Figs 3.10). 
In addition some cells presented with lateral plasma membrane protrusions, blebs, further 
suggesting that the cells where undergoing cell death, as this feature is characteristic of cells 
undergoing cell death especially via apoptosis (Majno and Joris, 1995).   
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Table 3.4: Summary of MUC1 and P65 co-localisation 
 MUC1  P65  Blebbing 
Controls;  
 Negative  
 Diluent 
Uniformly 
expressed across 
the cytoplasm, 
expression slightly 
reduced in diluent 
Uniformly 
expressed in the 
peri nuclear region, 
expression slightly 
reduced in diluent  
Absent 
NRTIs; 
 FTC 
 TDF 
Sparse cytoplasmic 
expression 
Decreased 
expression in the 
peri nuclear region 
Present 
NNRTIs; 
 EFV 
Sparse cytoplasmic 
expression 
Decreased 
expression in the 
peri nuclear region 
Present 
ATP combination; 
 FTC+TDF+EFV 
Sparse cytoplasmic 
expression 
Decreased 
expression in the 
peri nuclear region 
Present 
PI; 
 LPV/r 
Sparse cytoplasmic 
expression 
Decreased 
expression in the 
peri nuclear region 
Present 
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20µm 
Figure 3.2: Representative 
micrograph showing untreated 
HCS-2 cells (negative control).  
MUC1 was localised with anti-
MUC1 rabbit monoclonal 
antibody and goat polyclonal to 
rabbit IgG conjugated with 
TRITC (red fluorochrome). P65 
was localised with anti-NFkB 
P65 mouse monoclonal antibody 
and goat polyclonal to mouse 
IgG conjugated with FITC 
(green fluorochrome). The nuclei 
were counterstained with Dapi 
(blue). 
 
20µm 
 
Figure 3.3: Representative 
micrograph showing HCS-2 
cells treated with 0.02% 
methanol (diluent control).  
MUC1 was localised with anti-
MUC1 rabbit monoclonal 
antibody and goat polyclonal to 
rabbit IgG conjugated with 
TRITC (red fluorochrome). 
P65 was localised with anti-
NFkB P65 mouse monoclonal 
antibody and goat polyclonal to 
mouse IgG conjugated with 
FITC (green fluorochrome). 
The nuclei were counterstained 
with Dapi (blue). 
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Figure 3.4: Representative 
micrograph showing MCF-7 cells 
(positive control).  MUC1 was 
localised with anti-MUC1 rabbit 
monoclonal antibody and goat 
polyclonal to rabbit IgG 
conjugated with TRITC (red 
fluorochrome). The nuclei were 
counterstained with Dapi (blue). 
 
20µm 
 
 
Figure 3.5: Representative 
micrograph showing MCF-7 cells 
(positive control).  P65 was 
localised with anti-NFkB P65 
mouse monoclonal antibody and 
goat polyclonal to mouse IgG 
conjugated with FITC (green 
fluorochrome). The nuclei were 
counterstained with Dapi (blue). 
 
20µm 
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Figure 3.6: Representative 
micrograph showing untreated 
HCS-2 cells (without primary 
antibodies). The primary 
antibody was omitted in order to 
determine whether the 
secondary antibody binds 
exclusively to their targets. 
Inconspicuous localisation of the 
secondary antibodies in the 
cytoplasm indicates that the 
primary antibody only binds to 
the specific target and no other 
regions within the cells. The 
nuclei were counterstained with 
Dapi (blue). 
 
20µm 
 
 
 
 
 
Figure 3.7: Representative 
micrograph showing HCS-2 cells 
treated with 1.8 µg/ml of FTC.  
MUC1 was localised with anti-
MUC1 rabbit monoclonal 
antibody and goat polyclonal to 
rabbit IgG conjugated with 
TRITC (red fluorochrome). P65 
was localised with anti-NFkB P65 
mouse monoclonal antibody and 
goat polyclonal to mouse IgG 
conjugated with FITC (green 
fluorochrome). The nuclei were 
counterstained with Dapi (blue). 
The arrows depict plasma 
membrane blebbing on the surface 
of the cells. 
 
20µm 
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Figure 3.8: Representative 
micrograph showing HCS-2 cells 
treated with 0.3 µg/ml of TDF.  
MUC1 was localised with anti-
MUC1 rabbit monoclonal 
antibody and goat polyclonal to 
rabbit IgG conjugated with 
TRITC (red fluorochrome). P65 
was localised with anti-NFkB 
P65 mouse monoclonal antibody 
and goat polyclonal to mouse 
IgG conjugated with FITC (green 
fluorochrome). The nuclei were 
counterstained with Dapi (blue). 
The arrows depict plasma 
membrane blebbing on the 
surface of the cells. 
 
 
20µm 
 
 
 
 
 
Figure 3.9: Representative 
micrograph showing HCS-2 cells 
treated with 4.07µg/ml of EFV.  
MUC1 was localised with anti-
MUC1 rabbit monoclonal 
antibody and goat polyclonal to 
rabbit IgG conjugated with 
TRITC (red fluorochrome). P65 
was localised with anti-NFkB P65 
mouse monoclonal antibody and 
goat polyclonal to mouse IgG 
conjugated with FITC (green 
fluorochrome). The nuclei were 
counterstained with Dapi (blue). 
The arrows depict plasma 
membrane blebbing on the 
surface of the cells. 
 
 
 
20µm 
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Figure 3.11: Representative 
micrograph showing HCS-2 cells 
treated with the PI cocktail LPV/r 
(combination ratio of 1LPV: 
1RTV of their Cmax).  MUC1 
was localised with anti-MUC1 
rabbit monoclonal antibody and 
goat polyclonal to rabbit IgG 
conjugated with TRITC (red 
fluorochrome). P65 was localised 
with anti-NFkB P65 mouse 
monoclonal antibody and goat 
polyclonal to mouse IgG 
conjugated with FITC (green 
fluorochrome). The nuclei were 
counterstained with Dapi (blue). 
The arrows depict plasma 
membrane blebbing on the 
surface of the cells. 
 
 
 
Figure 3.10: Representative 
micrograph showing HCS-2 cells 
treated with the drug cocktail, 
ATP (combination ratio 
1FTC:1TDF:1EFV of their 
Cmax).  MUC1 was localised 
with anti-MUC1 rabbit 
monoclonal antibody and goat 
polyclonal to rabbit IgG 
conjugated with TRITC (red 
fluorochrome). P65 was localised 
with anti-NFkB P65 mouse 
monoclonal antibody and goat 
polyclonal to mouse IgG 
conjugated with FITC (green 
fluorochrome). The nuclei were 
counterstained with Dapi (blue).  
 
 
20µm 
 
 
 
 
 
 
 
20µm 
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3.3 Morphological features observed in HCS-2 cells following treatment with 
antiretroviral drugs by means of Scanning Electron Microscopy 
Drug treatment induced prominent changes in the cell surface morphology and in order to 
ascertain whether the changes observed in treated cells were significantly different from the 
negative control (untreated cells) and diluent control (0.02% methanol), statistical analysis 
was conducted. The micrographs were assessed using a scoring system (table 2.4) prior to the 
statistical analysis. An F-test (Brown-Forsythe) was conducted in order to check for 
homogeneity of variances. Following which a one way ANOVA test was conducted in order 
to determine whether there was a significant difference between the treated cells and controls. 
A Tukey Kramer Post Hoc test was also conducted in order to determine where the 
significant differences between the means were present. The statistical tests were carried out 
independently for every morphological criteria tested. 
3.3.1 Cell connections 
Brown-Forsythe test showed that there was no significant difference between the variances 
(p=0.1). A one way ANOVA test showed that there was a significant difference in cell 
connections (Fig 3.12 and Fig 3.17) (as indicated by the lateral cytoplasmic protrusions of the 
cells, filopodia) between the different groups as shown in table 3.5 (p<0.05). A Tukey 
Kramer Post Hoc analysis (Appendix IV; table 7.8) showed that a significant difference 
existed between controls and all treated cells except ATP, thus suggesting that drug 
treatment, except treatment with ATP, significantly altered cell contacts. The micrographs 
show that there were relatively fewer and more damaged cell contacts in treated cells in 
comparison to controls. Further differences were observed between LPV/r and FTC, TDF and 
ATP in that LPV/r treated cells had relatively lesser and more damaged cell contacts than 
other treatment groups. 
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Table 3.5: The analysis of variance using a one way ANOVA test in order to assess changes 
in cell contacts between the various groups.  
Source DF Sum of 
Squares 
Mean Square F Ratio Prob> F 
Group 6 18.166667 3.02778 10.4782 <.0001* 
Error 77 22.250000 0.28896   
C. Total 83 40.416667    
*= p value is significantly different 
 
Figure 3.12: Changes observed in cell contacts in HCS-2 cells following treatment with 
antiretroviral drugs. There was a significant difference observed between the different groups 
(p<0.05). Drug treatment damaged and reduced the amount of contacts present; LPV/r 
resulted in the most reduction and damage in comparison to controls and other treatment 
groups. Bar graphs not connected by the same letter are significantly different, Tukey Kramer 
Post Hoc analysis. 
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3.3.2 Microvilli density and size 
Brown-Forsythe test showed that there was no significant difference between the variances 
(p=0.4) for microvilli density (Fig 3.18). In contrast for microvilli size (Fig 3.18) there was a 
significant difference between the variances (p<0.05). In order to normalise the data, it was 
transformed using log base10 (Keen, 1995). 
 A one way ANOVA test showed that there was a significant difference in microvilli density   
and size (Fig 3.13) between the different groups as shown in table 3.6, (p<0.05). A Tukey 
Kramer Post Hoc analysis for microvilli density (Appendix IV; table 7.9) showed that a 
significant difference existed between controls and TDF, ATP and LPV/r treated cells, 
Furthermore TDF and ATP were significantly different from EFV and 0.02% methanol. The 
results showed that the different drug treatments did not have a similar effect in altering 
microvilli density; EFV and FTC treatment showed the least reduction in microvilli density in 
comparison to the controls whereas ATP, TDF and LPV/r treatment resulted in significant 
reduction in microvilli density.  
For microvilli size, a Tukey Kramer Post Hoc analysis (Appendix IV; table 7.10) showed that 
a significant difference existed between controls and all the treated cells, thus suggesting that 
treatment with all the ARV drugs significantly reduced microvilli size. Furthermore TDF, 
ATP and LPV/r treatment resulted in more reduction of microvilli size in comparison to FTC 
and EFV treatment.   
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Table 3.6: The analysis of variance using a one way ANOVA test in order to assess changes 
in microvilli density and size (MD and MS, respectively) between the various groups. 
Source DF Sum of Squares Mean Square F Ratio Prob> F 
  
MD 
& 
MS  MD  MS  MD  MS  MD  MS  
MD & 
MS  
Group  6  14.738095  2.2936452  2.45635  0.382274  5.4823  37.7785  <.0001* 
Error  77  34.500000  0.7791495  0.44805  0.010119       
C Total  83  49.238095  3.0727947           
*= p value is significantly different 
 
Figure 3.13: Changes observed in microvilli density and size in HCS-2 cells following 
treatment with antiretroviral drugs. There was a significant difference observed between the 
different groups (p<0.05). Drug treatment reduced the size and density of microvilli although 
the changes were unique to each drug treatment. TDF, ATP and LPV/r treatment showed the 
most reduction in microvilli size and density in comparison to controls and other drug 
treatments. Bar graphs not connected by the same letter (per characteristic) are significantly 
different, Tukey Kramer Post Hoc analysis. 
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3.3.3 Blebbing density and size 
Brown-Forsythe test showed that there was no significant difference between the variances 
for blebbing density (p= 0.7) and size (p= 0.3) (Fig 3.19). A one way ANOVA test showed 
that there was a significant difference in blebbing density and size between the different 
groups as shown in table 3.7 (p<0.05) (Fig 3.14).  
A Tukey Kramer Post Hoc analysis (Appendix IV; table 7.11) for blebbing density showed 
that a significant difference existed between the controls and ATP and TDF treated cells only, 
whereas no significant difference was observed between controls and FTC, EFV and LPV/r 
treated cells. The results suggest that the density of blebs in ATP and TDF were significantly 
higher than those observed in other groups. Although blebbing density in some treatment 
groups was not significantly different from the controls, the bleb density was still the least in 
controls therefore suggesting that high bleb formation was induced by drug treatment.  
For bleb size, a Tukey Kramer Post Hoc analysis (Appendix IV; table 7.12) showed that a 
significant difference existed between EFV treated cells and the other groups (i.e. Controls 
and other drug treatments). The results suggest that the size of the blebs observed following 
treatment with EFV were significantly larger than blebs observed in other groups which 
varied between small and medium sized.  
Table 3.7: The analysis of variance using a one way ANOVA test in order to assess changes 
in blebbing density (BD) and size (BS) between the various groups. 
Source DF Sum of Squares Mean Square F Ratio Prob> F 
  
BD 
& 
BS  BD  BS  BD  BS  BD  BS  BD  BS  
Group  6  18.976190  24.50000  3.16270  4.08333  4.0197  4.1100  0.0015*  0.0012* 
Error  77  60.583333  76.50000  0.78680  0.99351         
C 
Total  83  79.559524  101.00000             
*= p value is significantly different 
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Figure 3.14: Changes observed in blebbing density and size in HCS-2 cells following 
treatment with antiretroviral drugs. There was a significant difference observed between the 
different groups (p<0.05). The expression of blebs increased with drug treatment, thus 
controls showed the least expression of small sized blebs. TDF and ATP treatment resulted in 
high bleb density, whereas EFV treatment resulted in large sized blebs in comparison to 
controls and other treatment groups. Bar graphs not connected by the same letter (per 
characteristic) are significantly different, Tukey Kramer Post Hoc analysis. 
3.3.4 Cell shape 
Brown-Forsythe test showed that there was no significant difference between the variances 
(p=0.1). A one way ANOVA test showed that there was a significant difference between the 
groups in terms of the shape of the cell (Fig 3.15 and Fig 3.30) as shown in table 3.8, 
(p<0.05). A Tukey Kramer Post Hoc analysis (Appendix IV; table 7.13) showed that a 
significant difference existed between both controls and all the treated groups. In general, 
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drug treatment altered the shape of the cell in varying degrees. FTC, TDF and EFV treated 
cells acquired mostly a round shape; however, there were a few cells which were ovoid and 
some flattened, whereas ATP and LPV/r treated cells were mostly round in shape. Overall, 
cell shape changed from flattened and polyhedral in untreated cells to a transition between 
ovoid/oval to round in treated cells. 
Table 3.8: The analysis of variance using a one way ANOVA test in order to assess 
differences in cell shape between the various groups. 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob> F 
Group 6 15.107143 2.51786 6.5364 <.0001* 
Error 49 18.875000 0.38520   
C. Total 55 33.982143    
*= p value is significantly different 
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Figure 3.15: Changes observed in cell shape in HCS-2 cells following treatment with 
antiretroviral drugs. There was a significant difference observed between the different groups 
(p<0.05). Negative controls had a flattened and polyhedral shape; however the shape of the 
cell acquired a more rounded morphology following drug treatment. Treatment with ATP and 
LPV/r resulted in the most change in cell shape. Bar graphs not connected by the same letter 
are significantly different, Tukey Kramer Post Hoc analysis. 
3.3.5 The presence of membrane bound and extracellular secretions  
Brown-Forsythe test showed that there was no significant difference between the variances 
(p=0.1) for extracellular secretions (Fig 3.20). In contrast for membrane bound secretion (Fig 
3.20) there was a significant difference between the variances (p<0.05) (Fig 3.16). In order to 
normalise the data, it was transformed using log base10 (Keen, 1995). 
 A one way ANOVA test showed that there was a significant difference in the presence of 
membrane bound secretions between the different groups as shown in table 3.9 (p<0.05). A 
Tukey Kramer Post Hoc analysis (Appendix IV; table 7.14) for membrane bound secretions 
showed that a significant difference existed between both controls and treated cells; negative 
control had no secretions on their surface and 0.02% diluent control had few secretions 
whereas the drug treated cells had a significant amount of secretions on their surface. Further 
differences were observed between treated cells in that FTC and TDF had slightly less 
secretions on their surface than EFV, ATP and LPV/r which had more secretions in 
comparison. 
For extracellular secretions, a Tukey Kramer Post Hoc analysis (Appendix IV; table 7.15) 
showed that both controls and FTC were significantly different to TDF, ATP and LPV/r 
groups in that the former had none to a few secretions in its extracellular space whereas the 
latter three groups had significantly more secretions in its extracellular space. 
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Table 3.9: The analysis of variance using a one way ANOVA test in order to assess the 
presence of membrane bound and extracellular secretions between the various groups. 
Source DF Sum of Squares Mean Square F Ratio Prob> F 
  
MS 
& 
ES  MS  ES  MS  ES  MS  ES  MS & ES  
Group  6 0.9166667 7.619048 0.152778 1.26984 9.6359 6.2411  <.0001* 
Error  77 1.2208333 15.666667 0.015855 0.20346 
  
  
C Total  83 2.1375000 23.285714           
*= p value is significantly different 
 
Figure 3.16: The presence of membrane bound secretions in HCS-2 cells following treatment 
with antiretroviral drugs. There was a significant difference observed between the different 
groups (p<0.05). Untreated cells had very few if any secretions on their surface whereas 
treated cells had secretions in varying amounts with ATP and LPV/r having the most 
membrane-bound secretions. In contrast both controls (negative and diluent) and FTC treated 
cells had very few if any secretions in the extracellular space and were hence significantly 
different from ATP, LPV/r and TDF treated cells which had more secretions in the ECM. 
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Table 3.10: Summary table showing the comparison between morphological features observed in the HCS-2 cells following treatment with 
antiretroviral drugs. 
 Controls; negative and 
diluent 
NRTIs; FTC and TDF NNRTI; EFV Drug cocktails; ATP and 
LPV/r 
Cell contacts many few 
Microvilli density and size Dense and long in negative 
control s slightly reduced in 
density and length in diluent 
controls 
Relatively less dense and  short 
 
Bleb density and size Sparse and small blebs Uniformly spread across the 
PM, medium sized 
Large and sparsely 
distributed across the PM 
Uniformly spread across the 
PM, medium sized 
Cell shape Cells were flattened and 
polyhedral shaped in 
negative controls and a 
mixture of flattened and 
ovoid, with very few round 
cells in diluent controls 
Mostly round, with a few ovoid cells All the cells acquired a round 
shape 
Membrane-bound 
secretions 
No distinct secretions 
observed in negative controls 
whereas a few cells had 
small secretions on their 
surface in diluent controls 
A few secretions were observed scattered across the membrane and concentrated  towards the 
cell periphery and along the filopods 
Extracellular matrix 
secretions 
No distinct secretions were 
observed 
Very few if any secretions 
were present in the ECM 
with FTC treatment, however 
a few secretions were present 
following treatment with 
TDF 
Very few if any secretions 
were present in the ECM 
A few secretions were 
present in the ECM 
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  (g) 
    (f)   (e) 
 (d)   (c) 
(b) (a) 
 
Controls; 
 
Drug combination; 
NRTIs; 
NNRTI; 
 
Figure 3.17: The change in cell contacts 
following drug treatment in HCS-2 cells; (a) 
Negative control, (b) Diluent control, (c) ATP, 
(d) LPV/r, (e) FTC, (f) TDF, (g) EFV. The 
arrows show where cell contacts are found 
represented by long lateral protrusions, 
filopodia. Extensive cell contacts were 
characteristic in (a), with drug treatment as 
observed in (b-g) they were reduced and some 
were damaged in varying degrees.  
 
64 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.6: The change in cell contacts 
following drug treatment in HCS-2 cells; (a) 
Negative control, (b) Diluent control, (c) 
ATP, (d) LPV/r, (e) FTC, (f) TDF, (g) EFV. 
The arrows show where cell contacts are 
found represented by long lateral 
protrusions, filopodia. Extensive cell 
contacts were characteristic in (a), with drug 
treatment as observed in (b-g) they were 
reduced and some were damaged in varying 
degrees.  
    (g) 
   (f)   (e) 
   (d)   (c) 
  (b)  (a) 
Figure 3.3.7: The change in density and size of 
microvilli (mv) following drug treatment (arrows 
highlight the length of mv) ; (a) Negative control, 
(b) Diluent control, (c) ATP, (d) LPV/r, (e) FTC, 
(f) TDF and (g) EFV. In all the treated cells (b-g) 
microvilli density decreased in comparison to (a) 
and the microvilli observed in (c-f) were shorter 
in comparison to (a) and those seen in (g) were 
slightly shorter than those in (a), but longer than 
those seen in other drug treatments (c-f).  
Controls; 
Drug combination; 
NRTIs; 
NNRTI; 
 
Figure 3.18: The change in density and size of 
microvilli (mv) following drug treatment (arrows 
highlight the length of v) ; (a) egative control, 
    .       
microvilli density decreased in comparison to (a) 
and the microvilli observed in (c-f) were shorter 
in comparison to (a) and those seen in (g) were 
slightly shorter than those in (a), but longer than 
those seen in other drug treatments (c-f).  
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Controls; 
Drug combinations; 
NRTIs; 
NNRTI; 
 
 
 
Figure 3.19: The change in bleb density (B) and 
size following drug treatment; (a) Negative 
control, (b) Diluent control, (c) ATP, (d) LPV/r, 
(e) FTC, (f) TDF and (g) EFV. A few small 
blebs were observed in controls (a-b), drug 
treatment increase the amount and size of blebs, 
as seen in micrographs (c-g), in comparison to 
controls. 
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Controls; 
Drug combinations; 
NRTIs; 
NNRTI; 
 
 
Figure 3.20: cell secretions and change in cell 
shape following drug treatment; (a) Negative 
control, (b) Diluent control, (c) ATP, (d) 
LPV/r, (e) FTC, (f) TDF and (g) EFV. Arrows 
indicate extracellular secretions whereas circles 
represent membrane-bound secretions. The cell 
shape changed from flattened polyhedral in (a) 
to ovoid and/or circular in (b-g). 
(g) 
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CHAPTER FOUR: DISCUSSION 
In this study the treatment of HCS-2 cells with ARV drugs classified as NRTIs, NNRTI and 
PIs induced cell death. The gene and protein expression of MUC1 and P65 supports this 
finding and morphological features observed on the cell surface of the treated cells were 
characteristic of cell death.   
MUC1 is an oncogene and thus makes a suitable therapeutic target against cancer (Klinge et 
al., 2011). In many cancers the over expression of MUC1 signals reduced survival for 
patients because it promotes cancer, therefore inhibiting the function of MUC1 is an 
important target for therapeutic intervention (Klinge et al., 2011). MUC1 expression at 
appropriate levels is important for the normal function of organs and plays a role in 
producing protective mucous over epithelial surfaces (Klinge et al., 2011).  
MUC1 is over expressed in cancers and its expression has been linked to metastasis in breast 
cancer (Yuan et al., 2007). The MUC1 protein undergoes post translational proteolytic 
cleavage which results in the formation of two MUC1 subunits forming a heterodimer on the 
cell membrane (Yuan et al., 2007). The cytoplasmic domain of MUC1 has been shown to 
bind to epidermal growth factor receptor (EGFR) family members, c-Src and β-catenin, 
suggesting that MUC1 plays a role in cell growth related pathways and signal transduction 
(Yuan et al., 2007).  
In this study the gene and protein expression of MUC1 were studied. The expression of 
MUC1 protein was observed in the cytoplasm and along the cell membrane as previously 
mentioned in literature. Gene expression studies showed that treatment with MUC1 
expression was reduced following treatment with two drug cocktails; the first cocktail (ATP) 
consisted of two NRTIs (FTC and TDF) and one NNRTI (EFV) and it slightly reduced 
MUC1 expression in comparison to the control and the second cocktail (LPV/r). In contrast 
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the second cocktail (LPV/r) consisted of two PIs (LPV and RTV) and it resulted in a 
significant reduction in MUC1 expression in comparison to the control and the first cocktail 
(ATP). The drugs also reduced MUC1 protein expression; the drug cocktails both reduced 
protein expression and the reduction correlated with gene expression because LPV/r reduced 
MUC1 protein expression more than ATP. When the effects of the individual components of 
ATP were tested on MUC1 protein expression, only FTC and EFV treatment showed a 
significant reduction in MUC1 protein expression in comparison to the control.     
The reduction of MUC1 expression suggests that its capacity to regulate cell growth and 
signalling pathways is compromised and in this state, cells are more susceptible to cell death 
stimuli. This finding concurs with other studies which have found that most PIs promote cell 
death in vitro and in vivo (Gills et al., 2007; Vlahakis et al., 2007; Israr et al., 2011). 
Although different parameters were investigated in the different studies it is evident that these 
drugs target a variety of signalling proteins and pathways in order to exhibit their cell death 
effect. 
The NFkβ complex consists of P65 (Rel A) and P50 (NFkβ1), and is a diverse nuclear 
transcription factor that plays a role in regulating the expression of several genes that play a 
role in carcinogenesis and inflammation, for example, cyclin D1, c-myc, bcl-2, 
cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) (Jutooru et al., 
2010; Xia and Xue, 2012). The NFkβ-IkB complex lies in the cytosol when it is inactive 
(Jutooru et al., 2010; Xia and Xue, 2012). Its activation relies upon phosphorylation and 
proteosome dependant degradation of IkB therefore NFkβ accumulates in the nucleus when it 
is activated (Jutooru et al., 2010; Xia and Xue, 2012). The activation of NFkβ in cancer cells 
promotes cell proliferation, survival, angiogenesis, metastasis, epithelial to mesenchymal 
transition and inflammation (Jutooru et al., 2010; Xia and Xue, 2012).  
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In this study, a reduction in gene and protein expression of P65 was observed following drug 
treatment. The protein was inconspicuously expressed in the cytoplasm and mainly in the 
peri-nuclear region, there was no nuclear expression observed. The cytoplasmic expression of 
the protein suggests that it was either inactive or its activation was inhibited as described in 
literature; that cytoplasmic expression of P65 corresponds to an inactive form of the protein 
(Jutooru et al., 2010; Xia and Xue, 2012). This finding suggests that cell proliferation, 
angiogenesis, metastasis and other features of cancer regulated by this protein were reduced 
in the HCS-2 cells, therefore suggesting that the cells were more susceptible to cell death 
when compared to cell survival.  
Cell death is regulated by different signalling molecules and pathways, in addition 
morphological features are important in describing the type of cell death that cells undergo 
(Majno and Joris, 1995). In response to death stimuli the morphology of the cell begins to 
change and these changes are unique depending on the type of cell death the cells are 
undergoing (Majno and Joris, 1995). 
Apoptosis is an energy-dependant, intrinsic and genetically controlled process where the 
organism removes damaged cells (Bjelaković et al., 2005). Apoptosis plays a vital role as one 
of the factors that regulate the equilibrium between cell death and cell proliferation (Van 
Engeland et al., 1997). In the majority of cancers this equilibrium is often lost due to 
disruptions to the apoptotic process (Van Engeland et al., 1997). 
Apoptosis involves a sequence of characteristic morphological features including cell 
shrinkage, membrane blebbing, nuclear fragmentation and chromatin condensation (Van 
Engeland et al., 1997; Saraste and Pulkki, 2000; Bjelaković et al., 2005). Apoptotic cells 
detach from their substratum in order to acquire a rounded morphology and surface microvilli 
and cell junctions, for example, desmosomes, are also lost due to the reorganisation of 
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cytoskeletal structures (Saraste and Pulkki, 2000; Bjelaković et al., 2005; Condello et al., 
2013). The course of cell death is orderly, thereby suggesting the presence of well preserved 
molecular pathways (Saraste and Pulkki, 2000). 
Scanning Electron Microscopy (SEM) has played an important role to date in contributing to 
the identification of a variety of cell death mechanisms, including necrosis, apoptosis, 
autophagy, oncosis, mitotic catastrophe, which are induced by disease or noxious stimuli 
(such as heat, radiation, hypoxia, or cytotoxic drugs) (Condello et al., 2013). The findings 
from this study with regard to apoptosis using SEM are in accordance with those of previous 
studies.  
The morphological analysis of the plasma membrane using the SEM has revealed features 
which are characteristic of apoptosis; for example rounding-up of cells, retraction of 
filopodia, blebbing and maintenance of plasma membrane integrity (Bjelaković et al., 2005; 
Bjelaković et al., 2005; Kroemer et al., 2009). These features are in contrast to those 
observed in other forms of cell death, specifically necrosis. Necrosis is characterised by 
morphological features such as increased cell volume (oncosis) and plasma membrane 
rupture (Kroemer et al., 2009)  
Eukaryotic cells respond to intra and extracellular signals by remodelling their sub-
membranous cytoskeleton which is reflected by changes in the plasma membrane (Fackler 
and Grosse, 2008; Norman et al., 2010). The cytoskeletal re-arrangements are regulated by 
small GTPases belonging to the Rho family and downstream signalling caspases and they 
result in the formation of distinctive types of actin-rich invaginations or protrusions including 
filopodia, lamellipodia, invadopodia, podosomes, phagocytic cups, and uropods that have 
specific biological functions (Fackler and Grosse, 2008; Norman et al., 2010). 
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 Filopodia are thin cytoplasmic protrusions which play a role in attaching the cells to the 
growth surface, assisting in cell migration and are important components of cell to cell 
junctions (Fackler and Grosse, 2008; Norman et al., 2010). They were the most common type 
of protrusion observed in the HCS2 cells in this study.  
Untreated cells presented with numerous filopodia which were extending from the cells to 
form connections with adjacent cells and to adhere to the substratum, a feature which is 
commonly observed in cancer cells due to their high migratory rate and because the cancer 
cells are highly active they maintain communication with neighbouring cells and therefore 
numerous cell contacts are a common feature (Fackler and Grosse, 2008; Norman et al., 
2010). These features were altered to varying degrees in cells which were treated with the 
ARV drugs as they acquired characteristic features of cell death.  
The treated cells displayed loss of cell contacts as indicated by the reduced amount of 
prominent cell extensions making contact with adjacent cells and fewer and damaged 
filopodia were observed in the extracellular space. The PI (LPV/r) drug combination resulted 
in more damaged cell contacts than the other drugs. These findings suggest an adverse effect 
of the drug treatments on the cell’s capacity for invasion, taking into account that metastasis 
is dependent on the cell’s mobility which is ensured by the actin content (Fackler and Grosse, 
2008; Norman et al., 2010).  
The destruction of actin rich structures such as filopodia weakens the cancer cells capacity to 
move, therefore the effect of the drugs on the HCS-2 cells suggest that they may potentially 
prolong onset of metastasis by reducing cancer cell mobility. The change in cell shape from 
polyhedral and flattened in untreated cells to acquiring a more rounded morphology in treated 
cells is also an indication of re-organisation of the cytoskeletal components (Hacker, 2000).  
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Blebs are bulky, round structures which can extend up to 2µm from the plasma membrane 
(Fackler and Grosse, 2008; Norman et al., 2010). The life cycle of blebs lasts for a short 
period ~1min and is characterised by rapid bleb expansion, a short stationary phase, and low 
retraction of the bleb to its point of origin in the plasma membrane (Fackler and Grosse, 
2008; Norman et al., 2010).  The formation of blebs is induced by various actions involving 
local disruption of membrane actin cortex interactions, which lead to rapid protrusion of the 
plasma membrane due to the internal hydrostatic pressure of the cell (Fackler and Grosse, 
2008; Norman et al., 2010).  
Early studies done on plasma membrane blebs have linked their expression to cell movement, 
as they were observed during the spreading of human conjunctiva cells and fibroblasts 
(Fackler and Grosse, 2008; Norman et al., 2010). In contrast to these observations plasma 
membrane blebs were later viewed as a consequence of apoptotic and necrotic processes, in 
which cells display prominent blebs that do not play a role in locomotion, although blebbing 
alone is not a pre-requisite for the execution of cell death programmes (Fackler and Grosse, 
2008; Norman et al., 2010). Non-apoptotic blebs tend to have a reversible nature whereas 
apoptotic blebs ultimately lead to the formation of apoptotic bodies (Fackler and Grosse, 
2008; Norman et al., 2010). 
In this study there were a few blebs observed on the surface of some untreated cells possibly 
for locomotion, but following drug treatment the HCS-2 cells had an increase in blebs of 
various sizes across the cell surface. The amount of blebbing varied in density and size 
between the treatment groups and these two parameters (density and size) were inversely 
proportional to one another. NRTIs (FTC and TDF) induced the formation of small to 
medium blebs however FTC treatment induced lesser bleb density than TDF treatment 
suggesting that TDF induced changes quicker or was more potent in terms of cell death 
induction than FTC.  
73 | P a g e  
 
The NNRTI EFV, was amongst the treatments that induced the least amount of bleb 
occurrence yet the size of the blebs observed following treatment with this drug were the 
largest. The ATP combination resulted in evenly distributed bleb density and medium sized 
blebs. These effects were intermediate of those caused by individual drug treatment. The PI 
combination (LPV/r) showed the least bleb density and smaller blebs.  
When the observation of plasma membrane blebbing is reconciled with other morphological 
features observed in the cells, it is more likely that it resulted from apoptosis induction rather 
than locomotion. As previously mentioned that blebbing alone cannot be considered to be 
indicative of apoptosis; this study showed that there were other features present which are 
known to be characteristic of apoptosis, therefore it is suggested that drug treatment induced 
some changes in the cytoskeleton that led to the formation of blebs. This feature was not 
prominent in untreated cells further supporting the hypothesis that it is a result of cell death 
induction, possibly through apoptosis, and eluding to the fact that drug treatment induced the 
change.  
Changes in cytoskeletal components are not only reflected by bleb formation but can also be 
shown by changes in surface microvilli (Condello et al., 2013). In this study drug treatment 
with NRTIs (FTC and TDF), NNRTI (EFV), ATP combination (FTC, TDF and EFV) and PIs 
(LPV/r) reduced microvilli density in contrast to the dense cover and long microvilli 
observed in untreated cells. FTC and EFV treatment showed less severe reduction in 
microvilli density and size than TDF and ATP and the PI combination; LPV/r showed the 
most reduction suggesting that the drugs do not exhibit their effects at the same pace. These 
changes concur with previous studies which suggest that the cytoskeleton, which forms the 
core of the microvilli (Lange and Gartzke, 2001), is subject to change in response to cell 
death stimuli which in this case were the ARV drugs. 
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Another relationship was observed between blebbing and microvilli density in the plasma 
membrane. On cell surfaces where there was a high density of blebs the surface microvilli 
cover was less dense, and where there was low to medium density of blebs the surface 
microvilli cover was correspondingly denser; in the latter case the blebs would be 
interspersed among the microvilli. This observation could be an indication of the sequence of 
events and possibly suggests that loss of microvilli occurs at an early stage of cell death and 
precedes bleb formation which occurs later.  
In addition because both these features (blebs and microvilli) arise from the cytoskeleton, 
microvilli integrity would be more dependent on an intact cytoskeleton and in cases where a 
cell is undergoing cell death this is more likely to occur at the initial stages of cell death 
induction because as time lapses, the cytoskeleton loses integrity and so do the microvilli 
hence they become shorter. Therefore it is suggested that microvilli gradually decreases in 
density and size and make way for bleb formation.  
In contrast the blebs are more likely to occur at a later stage following loss of microvilli 
because as previous studies have suggested, the blebs carry degraded products from within 
the cell and pinch off to become apoptotic bodies (Condello et al., 2013); hence an inverse 
relationship exists between these two morphological features.  
At a later stage of apoptosis, the cell condenses and disintegrates into apoptotic bodies which 
will be detected and removed by macrophages or adjacent cells through phagocytosis (Van 
Engeland et al., 1997; Condello et al., 2013).  Transmission electron microscopy studies have 
revealed the structure of apoptotic bodies and they are membrane bound vesicles containing 
cellular organelles, part of the cytoplasm and nuclear fragments (Condello et al., 2013). 
Failure of the apoptotic cell to be phagocytised, as is the case in isolated conditions like cell 
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culture, results in degradation which is similar to necrosis and thus cell death is said to be 
facilitated via secondary necrosis (Saraste and Pulkki, 2000). 
In this study the drug treated cells were observed to be releasing some internal cellular 
secretions into the extra cellular matrix (ECM) as indicated by cell debri in the ECM. These 
secretions are suggested to represent the end stage of cell death in which the blebs begin to 
pinch-off forming apoptotic bodies. These apoptotic bodies are released from the cell into the 
extracellular space so that they can be removed via phagocytosis, as previously mentioned 
(Condello et al., 2013). 
 Due to the absence of phagocytic cells, the apoptotic bodies were degraded and released their 
contents, thus the cell secretions represents their remnants. Some of the secretions were 
membrane bound and these were observed in all the treatment groups although in varying 
numbers. Extracellular secretions were the least in FTC and EFV and were relatively more 
abundant in TDF, ATP and LPV/r.  
In summary, the ARV drugs used in this study induced morphological features which are 
known to be characteristic of cell death, especially through apoptosis. Although there were 
slight differences between the different drugs, TDF seemingly induced morphological 
changes more rapidly than FTC even though these drugs belong to the same class of ARVs, 
NRTIs. EFV, like FTC, was a slower acting drug in terms of inducing morphological changes 
in the cells. The drug combinations were seemingly more effective than individual treatments 
in inducing cell death because morphological features observed following 24hours treatment 
were relatively more advanced than in individual treatments, although the PI combination 
LPV/r was more potent than the ATP combination in inducing cell death.  
The results obtained from this study suggest a novel role for reverse transcriptase enzyme 
inhibitors and protease inhibitors. The anti cancer properties exhibited by these drugs should 
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be further explored alongside other factors such as drug-drug interactions when administered 
with other chemotherapeutic drugs in order to investigate whether NRTI, NNRT and PI can 
provide novel chemotherapeutic agents in the future especially in cervical cancer and HIV 
because the prevalence of both diseases is high and it would be of great benefit to people 
affected by both illnesses to be able to take a combined treatment regime for both illnesses. 
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CHAPTER FIVE: CONCLUSION AND FUTURE STUDIES 
5.1 Conclusion 
This study revealed that the antiretroviral drugs used reduced the gene and protein expression 
of MUC1 and P65 in HCS-2 cells. The PI combination (LPV/r) had more distinct effects than 
the other drugs. This finding suggests that by reducing MUC1 and P65 gene and protein 
expression the cells were more susceptible to cell death stimuli and cell death pathways were 
more likely to be activated at this state. 
The morphological features observed following drug treatment; loss of cell contacts, reduced 
microvilli density and length, increased blebbing, formation of apoptotic bodies, are 
characteristic of cell death, especially through apoptosis, these observations suggests that the 
cells were undergoing death through apoptosis. 
 Furthermore the cell secretions are suggested to be contents of apoptotic bodies. In vivo 
apoptotic bodies are removed by macrophages; however, in an isolated system like cell 
culture where macrophages are not present to engulf the apoptotic bodies they undergo 
degradation which is similar to necrosis and they ultimately release their contents into the 
extracellular space and at this stage cell death is known as apoptotic-necrosis or secondary 
necrosis (Saraste and Pulkki, 2000; Majno and Joris, 1995).  
5.2 Future studies 
The antiretroviral drugs used in this study induced cell death through apoptosis and had no 
effect on the gene and protein expression of MUC1 and P65 except for LPV/r which reduced 
MUC1 expression, although the exact pathway/s they use in order to induce apoptosis has not 
yet been identified. Drugs that have the potential to induce apoptosis have long been targeted 
for novel cancer therapy (Plati et al., 2008). Future studies that can be conducted in order to 
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further investigate the potential of these drugs as novel cancer therapy include in vitro and in 
vivo studies where the ARV drugs will be combined with chemotherapeutic agents and their 
effects on key signalling pathways in cancer such as EGFR and HER2/ErbB-2, Ras, PKC, 
AKT/PKB and mTOR and angiogenesis (Bianco et al., 2006).  
In addition dose-dependent studies should be conducted in order to determine the optimal 
dosage of the drug to be used in combination with chemotherapy that will result in the best 
inhibition of cancer cell proliferation. Moreover an identification of key signalling proteins 
and pathways that are activated by the drugs during cell death will be useful in optimising 
them for cancer therapy. 
This kind of advancement is imperative, especially in light of the high risk and prevalence of 
HIV/AIDS and cervical cancer, particularly in a majority of developing countries. If cancer 
and HIV/AIDS treatment can be combined into one regimen, it will possibly reduce 
production costs of the medication, which will in turn reduce the cost of buying the 
medication. Consequently it will be more affordable to the public sector, for example public 
hospitals, thus ensuring that more women have access to and receive the treatment and 
ultimately it will lead to better manangement of the disease.  
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7. APPENDICES    
7.1 APPENDIX I:Cell culture solutions 
7.1.1 0.1M Phosphate buffered solution (PBS), ph 7.4 (1l) 
 8g NaCl 
 1.15g Na2HPO4 
 0.2g KCL 
 0.2g KH2PO4 
Dissolve the salts in 800ml of distilled water (dH2O), measure the pH using a pH meter and 
adjust using appropriate solution (either KCl or NAOH) to get a final ph of 7.4. Then add the 
remaining 200ml of dH2O to make up a final volume of 1l. 
7.1.2 Trypan blue exclusion method for viable cells  
 0.4% Trypan blue in PBS 
 Haemocytometer and coverslip 
 Pipette and tips 
 Inverted microscope 
Suspend cells in 1ml of medium (following harvesting with Trypsin-EDTA) and collect 10µl 
of the cell suspension into an Eppendorff tube. Dilute the cell suspension with 40µl of 0.4% 
Trypan blue to make up 50µl of cell suspension. Pipette 15µl of the cell suspension in Trypan 
blue onto a haemocytometer and observe the grid under the inverted microscope at 5X and 
20X magnification (Refer to figure 7.1 for the layout of the grid). Viable cells will appear 
unstained, whereas dead cells will engulf the Trypan blue dye and as a result will be stained 
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blue and are therefore excluded from cell counting. The live cells that lie within the large 
squares of the grid located at the corners are counted and cell counts are recorded. 
 
 
Figure 7.1: A diagram showing the haemocytometer with the blocks in which the cells were 
counted labelled alphabetically (A,B,C and D). Image obtained from: home.cc.umanitabo.ca 
7.1.3 Cell counting 
To calculate cell concentration per ml; 
 Get an average number of cells (n) in the four large squares 
 Using the following formula calculate the cell concentration in 1ml: 
     Cell concentration in 1ml= average number of cells counted per square (n) 
*dilution factor (dilution factor was 5 in this case)* 10
4
(conversion factor to convert 
10-4ml to 1ml) 
 To get the amount needed for seeding: 
X amount= no. of cells required/ concentration of cells in 1ml 
                 =Y ml * 1000 
                 = z µl 
 Therefore z µl is seeded in order to get the required number of cells.  
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7.2 APPENDIX II: Additional methods for qPCR 
7.2.1 Principle of quantitative real time Polymerase Chain Reaction 
(qPCR) and rationale for its use 
Polymerase chain reaction (PCR) amplifies and detects as little as one copy of a specific 
sequence of DNA by generating copies of a DNA template exponentially (Arya et al., 2005). 
Therefore it enables the quantification of the amount of starting target sequence and PCR 
product accumulated during the course of the amplification cycle (Arya et al., 2005). The end 
point of the PCR cycle is the plateaux phase and it is reached when polymerase reaction 
inhibitors are dominant within the template and the reagents are used up (Arya et al., 2005). 
At this phase the PCR reaction no longer produces the template at an exponential rate 
therefore quantifying PCR products during this phase is deemed unreliable (Arya et al., 
2005). The exponential phase is considered the most accurate phase of the PCR reaction 
where the amount of starting material of the template sequence can be determined (Arya et 
al., 2005). Real time PCR measures the amount of amplified product present during each 
stage of the PCR cycle, especially the exponential phase, and quantifies it; therefore it is 
considered to be superior to conventional PCR which measures the PCR products at the end 
of the plateaux phase (Invitrogen, 2008; Arya et al., 2005). If the starting material of the 
particular sequence was abundant, amplification is observed rapidly whereas if the starting 
material of the sequence was less abundant amplification will be observed at a later stage 
(Invitrogen, 2008). The amplified product is quantified by use of fluorescent probes (Taqman 
polymerase) or fluorescent DNA-binding dyes (SYB Green) (Invitrogen, 2008). In addition 
to performing the necessary temperature changes needed for the PCR cycles real time PCR 
thermocyclers are equipped to measure the increase in fluorescence emission during a PCR 
reaction and computer software plots an amplification plot using that data (Invitrogen, 2008).  
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Real time PCR has been widely used in various experiment such as mRNA expression 
studies, measure of DNA copy numbers in genomic or viral DNAs, gene expression studies 
in tissues and cells etc because it monitors the PCR reaction as it progresses in real time and 
it accurately measures the amount of PCR product at each cycle (Arya et al., 2005). Overall it 
is a rapid but precise method of measuring gene expression (Arya et al., 2005).  
7.2.2. RNA extraction method 
The cell suspension was centrifuged for 5 mins at 250Xg. The cell pellet collected at bottom 
of the tube and the supernatant was discarded. The cell pellet was resuspended in 600µl of 
lysis buffer (supplemented with 2% β-mercaptoethanol purchased from uniLAB) and mixed 
by pipetting. The sample was then pipetted into a QIAshredder spin column placed in a 2ml 
collecting tube (QIAGEN). Thereafter the sample was centrifuged at maximum speed for 2 
minutes. 360µl of ethanol was added onto the sample and mixed by pipetting; ethanol helps 
the RNA in binding to the silica membrane of the spin column. A maximum of 700µl of 
lysate was transferred into a Gene-JET RNA purification column inserted in a collecting tube. 
The column was centrifuged for 1 minute at 12000Xg, thereafter the collecting tube 
containing the flow through was removed from the column, the flow through was discarded 
and the collecting tube was placed back below the column. This step was repeated until all 
the lysate was transferred into the column.  
700µl of wash buffer1 (supplemented with 20% ethanol) was added into the Gene-JET RNA 
Purification column and the column was centrifuged for 1 minute at 12000X g. The flow 
through in the collecting tube was discarded and the column was placed back into the 
collecting tube. 600µl of wash buffer 2 (supplemented with 63% ethanol) was added to the 
Gene-JET RNA Purification column and centrifuged for 1 minute at 12000X g. The flow 
through in the collecting tube was discarded and the column was placed back into the 
93 | P a g e  
 
collecting tube. 250 µl of wash buffer 2 (supplemented with 63% ethanol) was added to the 
Gene-JET RNA purification column and centrifuged for 2 minutes at 12000X g. The 
collecting tube was emptied and placed back into the column and centrifuged for 2 minutes at 
12000X g. The collecting tube containing the flow through was discarded and the Gene-JET 
RNA purification column was transferred into a sterile 1.5ml microcentrifuge tube. 100µl of 
nuclease-free water was added into the Gene-JET RNA purification column membrane and 
centrifuged for 1 minute at 12000X g in order to elute RNA 
7.2.3 Nanodrop method 
Switch on the Nanodrop and wipe with RNase-free water and lab paper. Pipette 2µl of 
RNase-free water to initiate it and press ok. Click on nucleic acid and select RNA 
(constant=40) wipe Nanodrop with lab paper. Pipette 1.5µl of RNA sample onto the 
Nanodrop and click measure. The Nanodrop measures the concentration of RNA per µl and 
gives a value for the 260/280 ratio and 260/230 ratio.  
 260/280 ratio: measures nucleic acid purity, the ideal ratio ranges between 1.8- 2.1. 
 260/230 ratio: measures the level of contaminants in the sample from the preparation 
(ideal ratio greater than 1.5, ideally 2) 
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Table 7.1: Summary of the RNA concentrations and purification ratios per group 
Sample ID ~Cells/ml [RNA] ng/µl  260/280 260/230 
Untreated 1 1 378 500 59 2.0 1.92 
Untreated 2 7 100 000 265.4 1.96 2.26 
Untreated 3 6 737 500 306.6 2.02 1.95 
Methanol 1 8 250 000 595.8 2.01 2.17 
Methanol 2 6 237 500 701.7 2.04 2.10 
Methanol 3 6 637 500 168.3 1.97 2.17 
ATP 1 7 387 500 392.0 1.94 2.20 
ATP 2 4 012 500 452.3 1.97 1.93 
ATP 3 4 375 000 415.2 1.96 2.18 
LPV/r 1 3 787 500 423.3 1.95 2.25 
LPV/r 2 4 925 000 458.7 1.94 2.09 
LPV/r 3 4 537 500 386.0 1.98 2.19 
 
7.2.4 Genomic DNA removal from RNA preparations 
Add the following to an RNase free tube; 
 1µg RNA 
 1µl 10X reaction buffer with MgCl2 
 1µl DNaseI, RNase free 
 RNase free water to make up 10µl 
Incubate the mixture for 30minutes at 37°C. Add 1µl 50mM EDTA and incubate for 
10minutes at 65°C in order to inactivate DNaseI activity. The final concentration of RNA in 
the mixture will be 0.1µg/µl. 
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Table 7.2: The amount of RNA used in the cDNA reaction  
RNA sample Amount needed to 
make 1µg of RNA 
in cDNA reaction 
(µl) 
Nuclease-free 
water used (µl) 
Combined 
volume of 10X 
reaction buffer 
and DNaseI 
(µl) 
Total (µl) 
Untreated R1 7 1 2 10 
Untreated R2 4 4 2 10 
Untreated R3 3.5 4.5 2 10 
0.02% Methanol R1 1.7 6.3 2 10 
0.02% Methanol R2 1.5 6.5 2 10 
0.02% Methanol R3 6 2 2 10 
ATP R1 2.8 5.2 2 10 
ATP R2 2.3 5.7 2 10 
ATP R3 2.5 5.5 2 10 
LPV/r R1 2.4 5.6 2 10 
LPV/r R2 2.2 5.8 2 10 
LPV/r R3 2.6 5.4 2 10 
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7.2.5 cDNA synthesis (RNA and H2O combinations used) 
Table 7.3: The table show the various components of the master mix used for cDNA 
synthesis. 
 
 
 
 
 
 
 
 
10µl of the master mix was pipetted using filter pipettes into RNase-free 1.5 ml eppendorfs 
tubes and the corresponding amount of RNA and RNA-free H2O which together made up 
10µl was added to each reaction tube to make up a final reaction volume of 20µl with an 
RNA concentration of ~100ng/20µl reaction (Table 7.5). All the work was carried out on ice. 
Following master mix preparation the cDNA reaction was run in the Applied Biosystems 
GeneAmp PCR System 2400 machine under the conditions indicated in the table below.  
 
 
 
Component Volume per reaction (µl) 
10X RT buffer 2.0 
25X dNTP mix (100mM) 0.8 
10X RT random primers 2.0 
Multiscribe Reverse 
transcriptase 
1.0 
RNase inhibitor 1.0 
Nuclease-free H2O 3.2 
Total 10 
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Table 7.4: Table depicting thermocycler conditions for cDNA synthesis 
 Step1 Step2 Step3 Step4 
Temperature (°C) 25 37 85 4 
Time (minutes) 10 120 5 ∞ 
 
Table 7.5: The RNA and water combination that were used in order to synthesize cDNA 
from each sample. 
 
 RNA (µl) H2O (µl) Total (µl) 
Untreated R1 5 5 10 
Untreated R2 2 8 10 
Untreated R3 1.9 8.1 10 
0.02% Methanol 
R1 
2 8 10 
0.02% Methanol 
R2 
2 8 10 
0.02% Methanol 
R3 
2 8 10 
ATP R1 1.9 8.1 10 
ATP R2 2 8 10 
ATP R3 2 8 10 
LPV/r R1 2 8 10 
LPV/r R2 2 8 10 
LPV/r R3 2 8 10 
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The final volume of 10µl from table X together with the 10µl from the cDNA master mix 
made up a volume of 20µl which was then put into the Applied Biosystems GeneAmp PCR 
System 2400 machine for cDNA synthesis. 
7.2.6 Tukey Kramer Post Hoc test results 
Table 7.6: Analysis of means using Tukey-Kramer Post Hoc test for MUC1 expression, 
levels not connected by the same letter are significantly different. 
Level   
Untreated A  
ATP A  
0.02% methanol A  
LPV/r  B 
 
Table 7.7: Analysis of means using Tukey-Kramer Post Hoc test for P65 expression, levels 
not connected by the same letter are significantly different. 
Level  
Untreated A 
LPV/r A 
0.02% methanol A 
ATP A 
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7.3 APPENDIX III: Immunocytochemistry solutions and 
additional information 
7.3.1 4% Paraformaldehyde  
 4g Paraformaldehyde (PFA) 
 100ml PBS (pH 7.4) 
 Hot plate 
 NaOH 
Weigh out 4g of PFA and dissolve in 100ml of PBS (pH 7.4). Place the solution onto a hot 
plate heated to 60°C and stir with magnetic stirrer until all the PFA is dissolved. Then add a 
few drops of NaOH until the solution is clear. Filter the solution and adjust the pH to 7.4, 
autoclave then store the solution in the freezer until use. 
7.3.2 0.1M Citrate buffer, pH 6 
 Solution A; dissolve 10.5g of citric acid in 500ml distilled water 
 Solution B; dissolve 29.4g of sodium citrate in 1000ml distilled water 
To make up 500ml of citrate buffer mix 9ml of solution A and 41ml of solution B. 
7.3.3 Permeabilisation solution (0.25% Triton X-100 in PBS) 
 Triton X-100 
  PBS (pH 7.4) 
To make up 25ml of solution; add 62.5µl of Triton X-100 in 25ml of PBS (pH 7.4) 
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7.3.4 Blocking solution (10% normal serum in PBS) 
 Normal goat serum 
 PBS (pH 7.4) 
To make up 10ml of the solution add 1ml of normal goat serum to 9ml of PBS (pH 7.4). 
7.3.5 Antibody dilution solution (1% BSA/PBS) 
 5g Bovine serum albumin (BSA) 
 500ml PBS (pH 7.4) 
Dissolve 5g of BSA in 500ml of PBS (pH 7.4) to make up 500ml solution of 1%BSA in PBS. 
7.3.6 Principle of Laser Scanning Confocal Microscopy and rationale for its use  
The concept for the confocal microscope was proposed by Minsky in 1950s but it first 
became commercially available in 1987 (Zhang et al., 2013). The design for a Laser 
Scanning Confocal Microscope (LSCM) is derived from a conventional Light Microscope 
(LM), however the source of light is a laser instead of a mercury or xenon lamp as in the LM 
(Amos and White, 2003; Paddock, 2000). Unlike LM whereby the whole specimen is 
immersed in light and the image is visible by the naked eye, In the LSCM light and detection 
are restricted to a single, diffraction-limited point which is focused on the specimen by an 
objective lens and scanned across the specimen, thereby producing optical sections; images 
produced by means of scanning the specimen with a beam of light (Amos and White, 2003; 
Paddock, 2000). The confocal microscope eliminates out-of-focal-plane light by means of 
spatial filters therefore allows the detection of light from the focal plane (Zhang et al., 2013). 
Consequently it has high spatial resolution and signal-to-noise ratio; in addition it is capable 
of optically sectioning samples in the z axis in order to create 3D images of thick samples 
(Zhang et al., 2013). This technique is a non invasive process of sectioning specimen, 
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therefore it preserves cell and tissue integrity (Amos and White, 2003; Paddock, 2000). 
LSCM is equipped with sensitive photomultiplier detectors (PMTs) which are positioned 
behind a pin hole and are connected to a computer which controls the scanning mirrors and 
facilitates compilation and display of images (Amos and White, 2003; Paddock, 2000). The 
PMT detects light from the specimen and its output develops an image on the computer 
(Amos and White, 2003; Paddock, 2000).The obtained images are stored in the computer and 
can be analysed using a variety of computer software installed on the confocal computer or 
another computer (Amos and White, 2003; Paddock, 2000). LSCM is a valuable and essential 
instrument for the observation of fixed and live tissues/cells, which are often labelled with 
fluorescent probes through immunocytochemistry (Zhang et al., 2013). It has gradually 
become a vastly used tool in various disciplines for example tissue biology, cell biology, 
molecular biology, genomics, embryology, neurology, pathology, immunology etc. (Zhang et 
al., 2013; Amos and White, 2003; Paddock, 200). 
7.3.7 Antibody dilution for MUC1 and P65 primary antibodies 
Dilution 1:100 1:150 1:250 
Anti-MUC1 
antibody 
[EPR1023] 
(ab109185)    
Dilution 1: 250 1: 500 1: 1000 
Anti-NFkB 
p65 antibody 
[NF-12] 
(ab10437) 
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7.4 APPENDIX IV: SEM SOLUTIONS AND TUKEY 
KRAMER POST HOC TEST TABLES 
7.4.1. Principle of Scanning Electron Microscopy and rationale for its use  
Ernst Ruska and Max Knoll constructed the first prototype electron microscope in 1931 and 
since its commercialisation in 1939, they have enabled biologists to explore the interesting 
intracellular world and study surface morphology in more detail (Condello et al., 2013). The 
electron microscope has been shown to be superior to light microscope (LM) because it has 
better resolving power than a LM (Condello et al., 2013). Electron microscopes make use of 
an electron beam to form images with higher magnification and greater resolving power than 
a light microscope (Condello et al., 2013). The SEM is designed to provide information about 
the general morphology and surface structure of biological samples (Condello et al., 2013). In 
the SEM, an electron beam is focused and scanned within a narrow area on the specimen 
(Condello et al., 2013). Upon interaction of the primary incident beam electrons with the 
surface layer of the specimen, emissions of various signals which carry information about 
surface topography and composition are produced (Condello et al., 2013). The SEM is able to 
image bulk samples with a great depth of field therefore it produces images which are a good 
representation of the accurate 3 dimensional structure of the specimen (Condello et al., 2013). 
Surface morphology of the cells was of great interest in this study because the information 
gathered provides important information about the physiology of the cell and the sample 
preparation is simple and less damaging to the cells. 
7.4.2 0.1M Phosphate (NaPO4) buffer (pH 7.4) 
 Solution A; dissolve 78g NaH2PO4 2H2O in 500ml distilled water 
 Solution B; dissolve 8.9g Na2HPO4 2H2O in 500ml distilled water 
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To make up 500ml of phosphate buffer mix 140ml of solution A and 360ml of solution B. 
7.4.3 2.5% Formaldehyde/Glutaraldehyde 
 2ml of 25% Formaldehyde 
 2ml of 25% glutaraldehyde 
 6ml of distilled water 
 10ml of 0.1M phosphate buffer 
Mix the above solutions in order to make a final volume of 20ml of the fixative. 
7.4.4 1% Osmium Tetroxide  
 Ampoule of 2ml containing 4% Osmium tetroxide 
 Phosphate buffer 
Add 4ml of phosphate buffer to 2ml of 4% osmium tetroxide solution in order to dilute the 
percentage of osmium tetroxide to 1% and the final volume of the solution will be 6ml. 
7.4.5 Graded ethanol solutions 
 100% (pure) ethanol 
 Distilled water (dH2O) 
To make 100ml solution of 50% ethanol; mix 50ml of pure ethanol with 50ml dH2O. 
To make 100ml solution of 70% ethanol; mix 70ml of pure ethanol with 30ml dH2O. 
To make 100ml solution of 80% ethanol; mix 80ml of pure ethanol with 20ml dH2O. 
To make 100ml solution of 95% ethanol; mix 95ml of pure ethanol with 5ml dH2O. 
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7.4.6 Tukey Kramer Post Hoc test results  
Table 7.8: The analysis of means using a Tukey Kramer Post Hoc test in order to assess 
changes in cell connections between the various groups, levels not connected by the same 
letter are significantly different. 
Level     
Untreated A    
0.02% Methanol A B   
ATP A B C  
TDF  B C  
FTC  B C  
EFV   C D 
LPV/r    D 
 
Table 7.9: The analysis of means using a Tukey Kramer Post Hoc test in order to assess 
changes in microvilli density between the various groups, levels not connected by the same 
letter are significantly different. 
Level    
Untreated A   
0.02% Methanol A B  
EFV A B  
FTC A B C 
LPV/r  B C 
ATP   C 
TDF   C 
 
Table 7.10: The analysis of means using a Tukey Kramer Post Hoc test in order to assess 
changes in microvilli size between the various groups, levels not connected by the same letter 
are significantly different. 
Level     
Untreated A    
0.02% Methanol A    
FTC  B   
EFV  B C  
TDF   C D 
ATP    D 
LPV/r    D 
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Table 7.11: The analysis of means using a Tukey Kramer Post Hoc test in order to assess 
blebbing density between the various groups, levels not connected by the same letter are 
significantly different. 
Level   
ATP A  
TDF A  
EFV A B 
FTC A B 
LPV/r A B 
Untreated  B 
0.02% Methanol  B 
 
Table 7.12: The analysis of means using a Tukey Kramer Post Hoc test in order to assess 
changes in bleb size between the various groups, levels not connected by the same letter are 
significantly different. 
Level   
EFV A  
ATP A B 
TDF A B 
LPV/r A B 
FTC A B 
0.02% Methanol  B 
Untreated  B 
 
Table 7.13: The analysis of means using a Tukey Kramer Post Hoc test in order to assess 
differences in cell shape between the various groups, levels not connected by the same letter 
are significantly different. 
Level    
Untreated A   
0.02% Methanol A B  
TDF  B C 
EFV  B C 
FTC  B C 
ATP   C 
LPV/r   C 
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Table 7.14: The analysis of means using a Tukey Kramer Post Hoc test on transformed data 
in order to assess the presence of membrane bound secretions between the various groups, 
levels not connected by the same letter are significantly different. 
Level     
LPV/r A    
ATP A B   
EFV A B C  
TDF  B C  
FTC  B C  
0.02% Methanol   C D 
Untreated    D 
 
Table 7.15: The analysis of means using a Tukey Kramer Post Hoc test in order to assess the 
presence of secretions in the extracellular matrix between the various groups, levels not 
connected by the same letter are significantly different. 
Level   
TDF A  
ATP A  
LPV/r A  
EFV A B 
0.02% Methanol  B 
FTC  B 
Untreated  B 
 
 
 
 
 
 
 
 
